[{"text": "LIVE The latest news and updates on Trump's tariffs IDXX Gears Up for Q4 Earnings: What to Expect From the Stock? Zacks Equity Research Mon, Jan 27, 2025, 5:07 PM 5 min read In This Article: IDXX IDEXX Laboratories, Inc. IDXX is set to release fourth-quarter 2024 results on Feb. 3, before the opening bell. Find the latest EPS estimates and surprises on Zacks Earnings Calendar. In the last reported quarter, the company posted adjusted earnings per share (EPS) of $2.80, which surpassed the Zacks Consensus Estimate by 4.1%. IDEXX Laboratories\u2019 earnings beat estimates in three of the trailing four quarters and missed in one, the average surprise being 0.85%. IDXX\u2019s Q4 Estimates The Zacks Consensus Estimate for revenues is pegged at $936.8 million, indicating an increase of 3.9% from the year-ago figure. The Zacks Consensus Estimate for EPS is pegged at $2.40, indicating an increase of 3.4% from the year-ago figure. Estimate Revision Trend Ahead of IDXX\u2019s Earnings Estimates for fourth-quarter earnings have remained unchanged at $2.40 in the past 30 days. Let\u2019s explore how things might have progressed for the pet healthcare innovator ahead of the announcement. Factors Shaping IDXX\u2019s Q4 Performance Companion Animal Group (\u201cCAG\u201d) In the fourth quarter of 2024, CAG Diagnostics\u2019 recurring revenues are likely to have been supported by improvements in average global net prices and international organic gains. IDEXX Laboratories\u2019 strong execution of strategies might have been a key factor in international growth, reflected in its strong new business gains and more premium instrument placements, boosting the global premium instrument installed base expansion. The U.S. CAG Diagnostic\u2019s recurring revenues are likely to have benefited from new business gains, sustained high customer retention levels and net price realization. Diagnostic utilization per clinical visit must have continued to expand at the clinic level, resulting in higher diagnostic revenue dollars per clinical visit, including diagnostics. We expect the company to have effectively navigated the headwinds from broader cumulative macroeconomic factors affecting consumers and ultimately achieved solid organic CAG Diagnostic revenue growth in the to-be-reported quarter. IDEXX VetLab consumables are expected to have delivered strong organic growth, fueled by robust performance in the United States and international regions. IDEXX Laboratories had earlier planned to launch the inVue Dx Cellular Analyzer in the fourth quarter. Its expanding test menu for the Catalyst platform, including the new Pancreatic Lipase Test, is expected to have strongly favored the segment\u2019s revenues. Within the point-of-care business, IDEXX Catalyst SmartQC was recently launched in North America. Further, the initial customer response toward Velo, a modern pet owner engagement application, was positive. We expect these developments to have strongly favored the segment\u2019s revenues. Story Continues IDEXX Laboratories, Inc. Price and EPS Surprise IDEXX Laboratories, Inc. Price and EPS Surprise IDEXX Laboratories, Inc. price-eps-surprise | IDEXX Laboratories, Inc. Quote Additionally, in the third quarter, the company experienced continued strong growth from its Premium Hematology and SediVue platforms. We expect the trend to have continued in the fourth quarter of 2024, further boosting IDXX\u2019s revenues. Revenues in global rapid assays are also likely to have benefited from higher net price realization. Global lab revenues might have surged due to strong U.S. performance and growth in the international regions. Meanwhile, IDEXX Laboratories\u2019 reference lab, veterinary software and diagnostic imaging revenues are expected to have benefited from a recent acquisition of Greenline software and data platform. The unit\u2019s organic growth might have been led by robust recurring revenues, indicating the benefits of ongoing momentum in cloud-based software placements. The Zacks Consensus Estimate for CAG business revenues implies a decline of 0.04% year over year. Water The segment is likely to have achieved strong organic revenues in the fourth quarter due to increased volumes in the United States and Europe. The Zacks Consensus Estimate for the Water segment\u2019s revenues implies a decline of 9% year over year. Livestock, Poultry and Dairy (\u201cLPD\u201d) The division is likely to have experienced a revenue decline due to reduced swine testing in China and continued lower herd health screening revenues. The Zacks Consensus Estimate indicates a 7.2% year-over-year increase in LPD revenues for the fourth quarter of 2024. What Our Model Says for IDXX Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates. However, that is not the case here, as you can see below: Earnings ESP: IDEXX Laboratories has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they\u2019re reported with our Earnings ESP Filter. Zacks Rank: The company currently carries a Zacks Rank #4 (Sell). Top Stocks to Consider Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this reporting cycle. Argenx ARGX has an Earnings ESP of +44.82% and a Zacks Rank #2 at present. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. The company is expected to release fourth-quarter 2024 results on March 6. The Zacks Consensus Estimate for EPS implies a surge of 196.4% from the year-ago quarter\u2019s reported figure. Arcutis Biotherapeutics ARQT has an Earnings ESP of +7.97% and a Zacks Rank #2 at present. The company is expected to release fourth-quarter 2024 results on Feb. 25. ARQT\u2019s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 17.46%. Axogen AXGN has an Earnings ESP of +36.36% and a Zacks Rank #2 at present. The company is likely to release fourth-quarter 2024 results on March 4. The Zacks Consensus Estimate for EPS implies a surge of 166.7% from the year-ago quarter\u2019s reported figure. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report IDEXX Laboratories, Inc. (IDXX) : Free Stock Analysis Report AxoGen, Inc. (AXGN) : Free Stock Analysis Report argenex SE (ARGX) : Free Stock Analysis Report Arcutis Biotherapeutics, Inc. (ARQT) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AXGN", "date": "2025-01-27T17:07:00", "sentiment": {"score": 0.9425783548504114, "confidence": 0.9577736854553223, "probabilities": {"positive": 0.9577736854553223, "negative": 0.01519533060491085, "neutral": 0.027031030505895615}}, "embedding": [-0.06249893456697464, -0.03800995647907257, 0.10306297242641449, 0.02336280420422554, 0.041292015463113785, -0.034181147813797, 0.029552914202213287, 0.11245766282081604, 0.11733275651931763, 0.046949535608291626, -0.04812884330749512, 0.09314782917499542, 0.061423495411872864, 0.05080453306436539, -0.1270930916070938, -0.034361958503723145, 0.03192484378814697, -0.026216015219688416, -0.16746436059474945, 0.004702230915427208, -0.04537641629576683, -0.062798872590065, 0.09611792117357254, -0.05336915701627731, -0.018487175926566124, -0.021620910614728928, -0.09716664254665375, -0.07411879301071167, -0.07164312154054642, -0.028806917369365692, -0.08323473483324051, 0.16312198340892792, 0.033484674990177155, -0.10063312202692032, -0.03922870755195618, -0.10732978582382202, 0.04815973341464996, 5.536177195608616e-05, 0.04030092433094978, -0.02264132723212242, 0.026483381167054176, -0.05003438889980316, -0.13155627250671387, -0.008091437630355358, -0.08237811923027039, -0.11929164826869965, -0.024528667330741882, -0.009668129496276379, 0.010508403182029724, 0.06555723398923874, -0.09389933943748474, -0.06922930479049683, 0.09903742372989655, -0.008862477727234364, -0.055412545800209045, -0.0336766391992569, -0.11175896227359772, -0.0725230872631073, -0.010423311032354832, 0.04158446192741394, -0.008628221228718758, 0.004788827151060104, -0.013206266798079014, 0.10370709747076035, 0.07441268861293793, 0.0006873691454529762, -0.04921311140060425, 0.05948913097381592, -0.15001243352890015, -0.08110268414020538, 0.03573143854737282, -0.06790318340063095, -0.043905578553676605, 0.01830177567899227, 0.01527999248355627, 0.10561027377843857, 0.17930051684379578, 0.06314805150032043, 0.19110265374183655, -0.0734189823269844, 0.034654319286346436, 0.06918490678071976, 0.014168277382850647, -0.04002871364355087, 0.027080779895186424, 0.04037415236234665, 0.08748658746480942, 0.09519931674003601, 0.011423785239458084, 0.02664448879659176, 0.1161682978272438, -0.060589902102947235, -0.07128133624792099, 0.0010952046141028404, 0.13278864324092865, -0.024073386564850807, -0.056483350694179535, -0.01658925972878933, 0.13268384337425232, 0.038195427507162094, 0.08641713112592697, 0.0829450860619545, -0.0499550960958004, -0.03226155415177345, -0.08382289111614227, -0.15567827224731445, 0.03332572430372238, 0.03655185177922249, 0.05214110016822815, 0.051211677491664886, -0.13988171517848969, 0.01582019031047821, -0.015009159222245216, -0.03851333260536194, -0.0436488501727581, 0.12882253527641296, -0.033798083662986755, 0.015967179089784622, 0.18513821065425873, -0.07753154635429382, 0.11414526402950287, 0.01892484724521637, -0.07534894347190857, -0.013906597159802914, 0.013430168852210045, 0.09517727792263031, -0.13464221358299255, 1.2274786783090831e-32, -0.033867817372083664, 0.08053398132324219, -0.04150352254509926, -0.04286133497953415, -0.01611134596168995, -0.0239484291523695, -0.017566775903105736, 0.007241337094455957, -0.06663838028907776, -0.014561960473656654, -0.2311166226863861, 0.19469381868839264, -0.03495204821228981, 0.005353881977498531, 0.020478393882513046, -0.08201909065246582, -0.028381088748574257, 0.1115841269493103, 0.05088629573583603, 0.02941230498254299, 0.01669144816696644, -0.13999521732330322, 0.04188773036003113, 0.07696983218193054, 0.06675319373607635, 0.12642984092235565, -0.05635441839694977, 0.00849190540611744, -0.046088580042123795, 0.04311073198914528, -0.09436613321304321, -0.06858818233013153, 0.035074181854724884, -0.09260222315788269, -0.2019539177417755, -0.001133892685174942, -0.013879655860364437, -0.07873005419969559, 0.061913080513477325, 0.08930756151676178, 0.01670982502400875, 0.08693306148052216, -0.04239518567919731, -0.08067845553159714, -0.024036869406700134, 0.05184303969144821, -0.06519937515258789, 9.658024646341801e-05, -0.0022869929671287537, 0.053527262061834335, -0.06304603070020676, 0.05052565038204193, 0.03471720591187477, -0.13960157334804535, -0.022661777213215828, 0.030961835756897926, -0.029645517468452454, -0.16794846951961517, -0.028585530817508698, 0.0867767482995987, 0.03002646006643772, 0.19704079627990723, -0.041743844747543335, 0.07109436392784119, -0.07089131325483322, 0.1241011768579483, 0.0016909766709432006, 0.017092423513531685, -0.08284297585487366, 0.2465396672487259, -0.005263081751763821, -0.05479774624109268, 0.09413278102874756, -0.13472160696983337, 0.20757776498794556, -0.05854134261608124, -0.07312518358230591, 0.018287720158696175, 0.10481787472963333, 0.026425842195749283, -0.016021598130464554, 0.10185743123292923, -0.029805734753608704, -0.02112676575779915, 0.033432550728321075, 0.009765256196260452, 0.03617549687623978, 0.15527406334877014, 0.016765179112553596, 0.02326025627553463, 0.021900856867432594, -0.055544741451740265, -0.09121876209974289, 0.12338931858539581, -0.005971122533082962, -1.2236481830301348e-32, -0.030190683901309967, 0.11999695003032684, -0.00020077091176062822, -0.06145946681499481, -0.0821056216955185, -0.03065575659275055, 0.0898049920797348, 0.0521765872836113, 0.0790739580988884, -0.07727348059415817, 0.02609800361096859, 0.0794360563158989, -0.03243232145905495, 0.1618211269378662, -0.05497286468744278, -0.027092674747109413, -0.012167117558419704, -0.11888503283262253, 0.04442662373185158, -0.03633417934179306, 0.024718575179576874, 0.1612929105758667, -0.10119501501321793, 0.11627710610628128, -0.05237454175949097, 0.06778735667467117, 0.07489880919456482, 0.11841286718845367, 0.08044688403606415, -0.18764302134513855, -0.05649041756987572, -0.06028585880994797, -0.08131130039691925, 0.04911378026008606, -0.01160203106701374, 0.024759948253631592, 0.0613216795027256, -0.11722920835018158, -0.06374009698629379, -0.08891305327415466, 0.06357809156179428, -0.016707565635442734, -0.04287383705377579, 0.06771189719438553, 0.057873137295246124, 0.032643795013427734, 0.02813093736767769, -0.038512036204338074, 0.12311410158872604, 0.05490011349320412, -0.008913110010325909, 0.0537998229265213, -0.06579118967056274, 0.022123126313090324, -0.1840267777442932, 0.00443631736561656, -0.045720525085926056, -0.016954848542809486, -0.18499638140201569, 0.03051782213151455, 0.008617810904979706, 0.13267242908477783, 0.017372136935591698, 0.10762707889080048, -0.04006314277648926, 0.010250798426568508, 0.09713657200336456, -0.0797167420387268, 0.04737306386232376, -0.12008648365736008, -0.03775562345981598, 0.021477732807397842, -0.06798169761896133, -0.2043730914592743, -0.023849736899137497, 0.17792779207229614, -0.07090198993682861, -0.14644944667816162, -0.03518947586417198, -0.02156156674027443, 0.022347450256347656, -0.05951264500617981, 0.02927105501294136, 0.0019750171341001987, -0.06582514941692352, 0.09447592496871948, -0.014289467595517635, 0.11241176724433899, -0.04856931045651436, 0.002148448023945093, -0.10624056309461594, -0.13251417875289917, -0.1875481903553009, 0.05131430923938751, -0.018097085878252983, -1.0121344473645877e-07, 0.03840658441185951, -0.024391526356339455, -0.008076993748545647, -0.02021445520222187, 0.04666702449321747, -0.0418180413544178, -0.0349215529859066, 0.05194678157567978, 0.11863362789154053, 0.13318601250648499, 0.07629817724227905, 0.02603362314403057, -0.16413013637065887, 0.010765520855784416, -0.02699369192123413, 0.03362997993826866, -0.13214966654777527, 0.050643231719732285, -0.026560332626104355, -0.05966591089963913, -0.06783467531204224, 0.1466185450553894, 0.029384680092334747, -0.1774577647447586, 0.055648572742938995, -0.11774128675460815, -0.05827368423342705, 0.010938776656985283, -0.027679909020662308, -0.022302741184830666, -0.04445277899503708, 0.0165342316031456, -0.04714185744524002, -0.00930097233504057, 0.05210348591208458, -0.14992187917232513, 0.048649538308382034, 0.0008688438683748245, 0.14010445773601532, 0.06636519730091095, 0.02096935175359249, 0.033349182456731796, -0.05536457151174545, -0.04160965979099274, -0.06586571037769318, -0.10197789967060089, -0.17499132454395294, -0.06426502764225006, 0.12314873933792114, -0.14085045456886292, 0.01729099452495575, -0.03451977297663689, -0.008200704120099545, -0.07529981434345245, 0.06064700335264206, 0.036461394280195236, -0.0752396285533905, -0.11480716615915298, -0.07366590946912766, 0.09635864943265915, 0.09563817828893661, -0.22431126236915588, 0.11967091262340546, 0.04779060557484627], "changes": {"1wk": 1.5616217207539527}}, {"text": "LIVE The latest news and updates on Trump's tariffs Robust Analytical Instruments Segment Likely to Aid TMO's Q4 Earnings Zacks Equity Research Thu, Jan 23, 2025, 3:32 PM 6 min read In This Article: TMO Thermo Fisher Scientific Inc. TMO is slated to release fourth-quarter 2024 results on Jan. 30, before market open. See the Zacks Earnings Calendar to stay ahead of market-making news . Thermo Fisher\u2019s third-quarter earnings of $5.28 per share beat the Zacks Consensus Estimate by 0.6%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.63%. TMO\u2019s Q4 Estimates The Zacks Consensus Estimate for revenues is pegged at $11.25 billion, suggesting 3.3% growth from the prior-year quarter\u2019s reported figure. The consensus mark for earnings is pegged at $5.92 per share, indicating 4.4% growth from the year-ago quarter\u2019s reported numbers. Estimate Revision Trend Ahead of Earnings Estimates for Thermo Fisher\u2019s fourth-quarter earnings have remained unchanged at $5.92 per share in the past 30 days. Now, let's look at how things might have progressed for the MedTech major prior to the announcement. Factors at Play Thermo Fisher\u2019s Analytical Instruments segment is expected to have generated strong fourth-quarter sales, banking on its newly launched cutting-edge technologies. The segment is expected to benefit from its electron microscopy business. In the fourth quarter, the company introduced the Thermo Scientific Iliad (Scanning) Transmission Electron Microscope, which integrates a number of TMO\u2019s advanced analytical technologies into a seamless and user-friendly workflow. In the third quarter, the R&D 100 Awards honored Thermo Scientific Orbitrap Astral Mass spectrometer in the market disruptors special recognition category. Additionally, per management, the adoption of Thermo Scientific\u2019s Orbitrap Astral continues to be incredibly strong. We expect these developments to have contributed to TMO\u2019s fourth-quarter revenues. Per our model, Thermo Fisher\u2019s Analytical Instruments business should earn $2.19 billion in revenues, suggesting 7.5% growth year over year. Within the Life-Science Solutions segment, the company is likely to have experienced a sales decline due to the runoff of pandemic-related revenues. In May 2023, WHO declared an end to COVID-19 as a public health emergency. Within this segment, in the third quarter, the company launched the Applied Biosystems MagMAX Sequential DNA/RNA kit, which helps researchers identify unique insights into cancer-causing genetic alterations. Also, TMO introduced Invitrogen Vivofectamine Delivery Solutions, which delivers nucleic acids to multiple targets with therapeutic effects. These developments might have turned in favor of Thermo Fisher in the fourth quarter. Story Continues Meanwhile, the bioproduction business has likely grown in the quarter, banking on strong adoption in the pharma and biotech segment. Within this business, the company introduced Gibco CTS Detachable Dynabeads CD4 and CTS Detachable Dynabeads CD8, which expanded on Thermo Fisher\u2019s CTS Detachable Dynabeads platform. Meanwhile, TMO is expected to have gained from its successful acquisition of Olink Holding AB during the third quarter. Per our model, the Life-Science Solutions business is expected to have generated $2.65 billion in revenues for the fourth quarter, calling for a 7.5% improvement year over year. The Specialty Diagnostics segment (Clinical Diagnostics business from the molecular controls that go into testing kits) is expected to have gained positive contributions, led by its transplant diagnostics and immunodiagnostics businesses as well as the healthcare market channel. Additionally, during the fourth quarter, the company received approval from the Food and Drug Administration (\u201cFDA\u201d) for its Ion Torrent Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients eligible for treatment with VORANIGO tablets. Thermo Fisher Scientific Inc. Price and EPS Surprise Thermo Fisher Scientific Inc. Price and EPS Surprise Thermo Fisher Scientific Inc. price-eps-surprise | Thermo Fisher Scientific Inc. Quote In the previous quarter, TMO partnered with the National Cancer Institute on the myeloMATCH (Molecular Analysis for Therapy Choice) precision medicine umbrella trial. The company also launched a pre-transplant risk assessment assay to help assess the risk of early acute rejection in kidney transplant recipients. Moreover, it secured 510(k) FDA clearance for SeCore CDx HLA A Sequencing System for synovial sarcoma. We expect these developments to have had a positive impact on the company\u2019s fourth-quarter top-line performance. Our model projects TMO\u2019s Specialty Diagnostics business to report $1.13 billion in revenues, suggesting 2% growth year over year. Within the Laboratory Products and Services segment, revenues are expected to have increased due to the research and safety market channel. During the fourth quarter, the company introduced Thermo Scientific iCAP MX Series ICP-MS, designed for environmental, food, industrial and research labs to analyze routine and challenging trace elements to detect and mitigate harmful substances. During the third quarter, the company opened its first electron microscopy demo center, NanoPort, in Taiwan. TMO also expanded its global laboratory services with a new bioanalytical lab in GoCo Health Innovation City in Gothenburg, Sweden. This, too, while strengthening the company\u2019s foothold in Taiwan, might have had a favorable impact on TMO\u2019s top line in the to-be-reported quarter. Our model expects TMO\u2019s Laboratory Products and Services business\u2019 fourth-quarter revenues to be $5.72 billion, flat year over year. What Our Quantitative Model Predicts Per our proven model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below. Earnings ESP: Thermo Fisher has an Earnings ESP of +0.65%. You can uncover the best stocks to buy or sell before they\u2019re reported with our Earnings ESP Filter. Zacks Rank: The company currently carries a Zacks Rank #4. Stocks Worth a Look Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this reporting cycle. Argenx ARGX has an Earnings ESP of +44.82% and a Zacks Rank #2 at present. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. The company is expected to release fourth-quarter 2024 results on March 6. The Zacks Consensus Estimate for EPS implies a surge of 196.4% from the year-ago quarter\u2019s reported figure. Arcutis Biotherapeutics ARQT has an Earnings ESP of +7.97% and a Zacks Rank #2 at present. The company is expected to release fourth-quarter 2024 results on Feb. 25. ARQT\u2019s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 17.46%. Axogen AXGN has an Earnings ESP of +36.36% and a Zacks Rank #2 at present. The company is likely to release fourth-quarter 2024 results on March 4. The Zacks Consensus Estimate for EPS implies a surge of 166.7% from the year-ago quarter\u2019s reported figure. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report AxoGen, Inc. (AXGN) : Free Stock Analysis Report argenex SE (ARGX) : Free Stock Analysis Report Arcutis Biotherapeutics, Inc. (ARQT) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AXGN", "date": "2025-01-23T15:32:00", "sentiment": {"score": 0.8180302605032921, "confidence": 0.8689130544662476, "probabilities": {"positive": 0.8689130544662476, "negative": 0.050882793962955475, "neutral": 0.08020416647195816}}, "embedding": [-0.15029652416706085, 0.01356265228241682, -0.04373661428689957, 0.015694351866841316, -0.03873471915721893, -0.05987975001335144, -0.03491855785250664, 0.1828223019838333, 0.09697269648313522, 0.15428224205970764, -0.028911042958498, -0.008557874709367752, -0.015298545360565186, 0.062494710087776184, -0.0728696957230568, 0.04021897912025452, 0.05411752313375473, -0.07893823832273483, -0.03262528032064438, -0.001342384610325098, -0.025993091985583305, -0.004466328304260969, 0.10920925438404083, -0.056457486003637314, 0.13149164617061615, 0.04646989703178406, -0.08295443654060364, -0.009194623678922653, -0.15904678404331207, 0.07004845887422562, -0.20931267738342285, 0.186416357755661, 0.0708678662776947, -0.030381254851818085, -0.053003307431936264, -0.05733197182416916, -0.07360124588012695, -0.0009812740609049797, 0.14112257957458496, 0.017931204289197922, 0.01274587120860815, -0.01775370165705681, -0.08790762722492218, -0.03156749904155731, -0.08307838439941406, -0.11763501167297363, 0.1567973643541336, -2.5447458028793335e-05, 0.001200251281261444, 0.10645820200443268, -0.16827572882175446, -0.021353822201490402, 0.08534197509288788, 0.0849003866314888, -0.08962073922157288, 0.024792252108454704, -0.011978710070252419, -0.05940861999988556, 0.056685496121644974, 0.05680178105831146, -0.05098624899983406, -0.05460662767291069, -0.08941851556301117, 0.1077829971909523, 0.20242547988891602, -0.07252354174852371, -0.05351492762565613, 0.0166738573461771, -0.1591086983680725, 0.0011089947074651718, 0.06446748971939087, -0.004727215971797705, 0.02913251519203186, -0.06323905289173126, -0.05110844969749451, 0.04006864130496979, 0.25286588072776794, 0.05748552829027176, 0.22554461658000946, -0.08507640659809113, 0.11523790657520294, -0.09174473583698273, -0.11444050818681717, -0.07601260393857956, -0.11845012754201889, 0.025984980165958405, 0.05864812433719635, 0.1399778425693512, 0.12056226283311844, 0.028175609186291695, 0.0576801560819149, -0.06686288118362427, -0.1350412368774414, -0.08879362046718597, -0.00913897156715393, 0.0075102620758116245, -0.06175370141863823, 0.014371661469340324, 0.15890395641326904, 0.025753434747457504, 0.07012130320072174, 0.060068193823099136, -0.02046995982527733, -0.058579809963703156, -0.023948760703206062, -0.10385283827781677, 0.10484564304351807, 0.00011378247290849686, 0.11467719823122025, 0.08277322351932526, -0.10717734694480896, 0.059571780264377594, -0.05727289244532585, -0.014380425214767456, -0.03134235367178917, -0.003794414922595024, -0.015944791957736015, 0.10640748590230942, 0.16257545351982117, 0.0677470788359642, 0.11843858659267426, 0.05904153734445572, -0.013050558976829052, 0.021897856146097183, 0.02660558931529522, 0.05634260177612305, -0.15269868075847626, 7.988221736542585e-33, 0.03496640920639038, 0.11623675376176834, -0.024571510031819344, -0.039279282093048096, 0.012856228277087212, 0.053768157958984375, -0.041442517191171646, 0.02474214695394039, -0.09095782041549683, -0.06740763783454895, -0.1790652871131897, 0.15237194299697876, -0.08990315347909927, 0.02604643628001213, 0.09260013699531555, -0.038269925862550735, -0.08736816793680191, 0.03038271889090538, 0.011855902150273323, -0.03538385033607483, -0.015193415805697441, -0.05841727554798126, 0.006063544657081366, 0.19844892621040344, 0.03491661697626114, 0.16363441944122314, -0.010640335269272327, -0.007405543699860573, -0.16792164742946625, 0.08100606501102448, -0.006075841374695301, 0.042957134544849396, -0.011045117862522602, -0.2068665623664856, 0.04431065171957016, -0.07486575841903687, -0.07056836038827896, -0.008460167795419693, 0.14707976579666138, 0.03207054361701012, -0.0334402434527874, 0.11175317317247391, -0.0871073380112648, -0.05809354782104492, -0.09351444989442825, 0.01786722056567669, -0.023831946775317192, 0.027892982587218285, 0.13399015367031097, -0.003149242140352726, -0.04868873208761215, -0.04038185626268387, -0.009698055684566498, -0.18324145674705505, -0.021843891590833664, 0.004339324310421944, -0.08223608881235123, -0.15443937480449677, 0.13079825043678284, 0.07929178327322006, -0.04645897075533867, 0.17916236817836761, 0.022976592183113098, 0.04325798153877258, -0.08513609319925308, 0.23941372334957123, 0.013145928271114826, -0.0046608601696789265, 0.0036678053438663483, 0.11761447042226791, -0.05110001191496849, -0.08208579570055008, 0.08400548249483109, -0.11860111355781555, 0.09965582191944122, 0.008135175332427025, 0.014845398254692554, -0.07262683659791946, 0.12774132192134857, -0.010181184858083725, -0.01651328057050705, -0.0751371830701828, 0.11585430055856705, -0.09103157371282578, 0.004090756177902222, -0.07247083634138107, -0.039715126156806946, 0.05567971616983414, 0.010378628969192505, -0.037095341831445694, 0.09777866303920746, -0.12204522639513016, -0.10920004546642303, 0.0972304567694664, -0.05104561895132065, -9.472597064510598e-33, -0.13711684942245483, 0.09089668840169907, -0.07531777024269104, -0.031580157577991486, -0.12778815627098083, -0.035455189645290375, 0.01652250438928604, 0.07154155522584915, 0.06322638690471649, -0.03199418634176254, 0.02047974430024624, 0.09773316979408264, -0.11426808685064316, -0.023041486740112305, -0.015618114732205868, 0.032487109303474426, 0.03216639906167984, -0.09060053527355194, 0.001118387095630169, -0.0374809205532074, 0.10980772972106934, 0.10015733540058136, -0.09898672252893448, 0.0985245630145073, 0.027819547802209854, 0.07925108075141907, -0.00296989269554615, 0.014310176484286785, 0.061439838260412216, -0.013008729554712772, -0.0678306445479393, -0.14987745881080627, -0.06160491704940796, 0.015696648508310318, 0.057831570506095886, 0.0011411551386117935, 0.09454323351383209, -0.1023949384689331, 0.07668168097734451, -0.10232175886631012, 0.24493801593780518, -0.013642381876707077, 0.03801221027970314, -0.03998959809541702, 0.0043050991371273994, -0.023312294855713844, -0.01969640702009201, -0.02670004963874817, 0.08852233737707138, 0.0746212750673294, 0.03616189956665039, 0.0134089644998312, -0.05376119539141655, -0.04187614098191261, -0.13376109302043915, 0.021672798320651054, -0.022344714030623436, -0.015187764540314674, -0.134418785572052, -0.01831991970539093, 0.01782114990055561, 0.06134123355150223, 0.04140768200159073, 0.04614701867103577, -0.06424873322248459, 0.06356728076934814, 0.08154459297657013, -0.04802774637937546, 0.06286917626857758, -0.10721857100725174, 0.026546893641352654, -0.05768802389502525, 0.0532258078455925, -0.2734222412109375, -0.041583333164453506, 0.20438355207443237, -0.05077773332595825, -0.1408030092716217, -0.004582099616527557, 0.007571539841592312, -0.026193030178546906, 0.1030232310295105, 0.11778153479099274, -0.015723012387752533, 0.02353799156844616, 0.02610580436885357, 0.06785685569047928, -0.02369506284594536, -0.1372225284576416, -0.007987301796674728, -0.05342160910367966, -0.16132821142673492, -0.0671641081571579, 0.04674699530005455, 0.08456850051879883, -1.0060536936862263e-07, 0.1048172265291214, -0.034554027020931244, 0.04228007793426514, -0.055738020688295364, 0.15546226501464844, -0.06605799496173859, -0.008965443819761276, 0.0937059074640274, 0.15732872486114502, 0.154179185628891, 0.07913386821746826, 0.04017382487654686, -0.1218966543674469, 0.05379866063594818, -0.0388912633061409, 0.017624691128730774, -0.13749101758003235, -0.021633047610521317, -0.133350670337677, -0.1359262764453888, 0.006483284290879965, 0.030070066452026367, 0.07505704462528229, -0.13647565245628357, 0.0723273754119873, -0.02427930384874344, -0.15780231356620789, -0.009456532076001167, 0.006791085936129093, 0.002311980351805687, -0.07491835951805115, -0.047751493752002716, -0.08254829794168472, 0.08845001459121704, -0.0008430946618318558, -0.15674442052841187, 0.02106793038547039, -0.040210433304309845, 0.04657503217458725, 0.10708974301815033, -0.0012240936048328876, -0.004657006356865168, -0.012333758175373077, 0.06922993808984756, -0.08332454413175583, -0.04806721210479736, -0.19620317220687866, -0.01559107843786478, 0.029994260519742966, -0.058548882603645325, 0.07855943590402603, 0.002823213115334511, -0.13177666068077087, -0.0738736093044281, -0.02605782076716423, 0.030472632497549057, -0.017743613570928574, -0.061550039798021317, -0.16744773089885712, -0.032078929245471954, 0.12354917824268341, -0.2791484296321869, 0.014622990041971207, 0.043977584689855576], "changes": {"1wk": -2.0855683480505163}}, {"text": "LIVE The latest news and updates on Trump's tariffs AxoGen, Inc. (AXGN) Soars to 52-Week High, Time to Cash Out? Zacks Equity Research Mon, Jan 13, 2025, 5:35 PM 4 min read In This Article: AXGN PEN Have you been paying attention to shares of AxoGen (AXGN) ? Shares have been on the move with the stock up 27.5% over the past month. The stock hit a new 52-week high of $18.4 in the previous session. AxoGen has gained 9.5% since the start of the year compared to the -4.5% move for the Zacks Medical sector and the 6.5% return for the Zacks Medical - Instruments industry. What's Driving the Outperformance? The stock has an impressive record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on November 7, 2024, AxoGen reported EPS of $0.07 versus consensus estimate of $0 while it beat the consensus revenue estimate by 3.5%. For the current fiscal year, AxoGen is expected to post earnings of $0.31 per share on $185.2 million in revenues. Meanwhile, for the next fiscal year, the company is expected to earn $0.48 per share on $208.47 million in revenues. This represents a year-over-year change of 251.85% and 12.56%, respectively. Valuation Metrics AxoGen may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level. On this front, we can look at the Zacks Style Scores, as these give investors a variety of ways to comb through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. Investors should consider the style scores a valuable tool that can help you to pick the most appropriate Zacks Rank stocks based on their individual investment style. AxoGen has a Value Score of D. The stock's Growth and Momentum Scores are A and C, respectively, giving the company a VGM Score of B. In terms of its value breakdown, the stock currently trades at 57.6X current fiscal year EPS estimates, which is a premium to the peer industry average of 27.6X. On a trailing cash flow basis, the stock currently trades at 5X versus its peer group's average of 16.8X. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective. Zacks Rank We also need to consider the stock's Zacks Rank, as this supersedes any trend on the style score front. Fortunately, AxoGen currently has a Zacks Rank of #2 (Buy) thanks to rising earnings estimates. Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if AxoGen meets the list of requirements. Thus, it seems as though AxoGen shares could have a bit more room to run in the near term. Story Continues How Does AXGN Stack Up to the Competition? Shares of AXGN have been soaring, and the company still appears to be a decent choice, but what about the rest of the industry? One industry peer that looks good is Penumbra, Inc. (PEN) . PEN has a Zacks Rank of # 1 (Strong Buy) and a Value Score of C, a Growth Score of A, and a Momentum Score of F. Earnings were strong last quarter. Penumbra, Inc. beat our consensus estimate by 23.19%, and for the current fiscal year, PEN is expected to post earnings of $3.86 per share on revenue of $1.19 billion. Shares of Penumbra, Inc. have gained 2.1% over the past month, and currently trade at a forward P/E of 64.9X and a P/CF of 88.63X. The Medical - Instruments industry is in the top 35% of all the industries we have in our universe, so it looks like there are some nice tailwinds for AXGN and PEN, even beyond their own solid fundamental situation. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AxoGen, Inc. (AXGN) : Free Stock Analysis Report Penumbra, Inc. (PEN) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AXGN", "date": "2025-01-13T17:35:08", "sentiment": {"score": 0.3319201413542032, "confidence": 0.3523740768432617, "probabilities": {"positive": 0.3523740768432617, "negative": 0.020453935489058495, "neutral": 0.6271719336509705}}, "embedding": [-0.12548239529132843, -0.09310553967952728, 0.0430496521294117, -0.028726965188980103, 0.01746075227856636, 0.003703305497765541, -0.03582020476460457, 0.09538836777210236, 0.0938262790441513, 0.11518028378486633, -0.06094292178750038, 0.05618009343743324, -0.10579140484333038, -0.04692463204264641, -0.13800910115242004, 0.021953195333480835, 0.06108153238892555, -0.059118449687957764, -0.06710030883550644, 0.15033867955207825, 0.04737309366464615, -0.06818994134664536, 0.08090454339981079, -0.10899190604686737, 0.15315230190753937, 0.05491674691438675, -0.0505373477935791, 0.05336684361100197, -0.11006131023168564, -0.08025740087032318, -0.01769791729748249, 0.1152612641453743, 0.08225901424884796, -0.031235799193382263, -0.1449938714504242, -0.04162311553955078, 0.04435393959283829, 0.0746384710073471, 0.182835191488266, 0.038240909576416016, 0.07417337596416473, 0.06037377938628197, -0.04223901033401489, -0.03195822983980179, -0.10448914021253586, -0.13205136358737946, 0.05564124509692192, 0.020493386313319206, 0.0031222011893987656, 0.06819535046815872, -0.10659325122833252, -0.05209469422698021, -0.06396257132291794, 0.0642772912979126, -0.04851546138525009, 0.07807406783103943, -0.02968904748558998, -0.08021897822618484, 0.029582824558019638, 0.004344145301729441, -0.013992100022733212, 0.0794093906879425, 0.06795530021190643, -0.006394925527274609, 0.18025876581668854, 0.011511201970279217, -0.018130499869585037, 0.03954843059182167, -0.12132883071899414, 0.0404311865568161, 0.0806957334280014, 0.0327470526099205, -0.048817191272974014, -0.061501238495111465, -0.10865087807178497, 0.019941091537475586, 0.16196633875370026, -0.028735319152474403, 0.1306861937046051, -0.15748104453086853, 0.000508810393512249, 0.05663817375898361, -0.019387172535061836, -0.08174121379852295, 0.04454150050878525, -0.021343089640140533, 0.06873098015785217, 0.03191903978586197, 0.07995111495256424, 0.00796649232506752, 0.009258164092898369, -0.052937451750040054, -0.04756231606006622, -0.026397716253995895, 0.07742543518543243, 0.08810444176197052, -0.017536234110593796, -0.019232312217354774, 0.03605176508426666, 0.12259048968553543, 0.14682386815547943, 0.0954378992319107, -0.06919220089912415, -0.10911114513874054, 0.010425248183310032, -0.04738525301218033, 0.050312548875808716, -0.06753471493721008, -0.040638577193021774, 0.04637356847524643, -0.04307888448238373, 0.08028244972229004, -0.11888161301612854, -0.005083236377686262, -0.10904198884963989, -0.0025386689230799675, -0.01815314218401909, -0.0028881202451884747, 0.025343332439661026, 0.05994493141770363, 0.10166503489017487, 0.06574544310569763, 0.0056831734254956245, 0.015892283990979195, 0.04244234785437584, 0.00995264295488596, -0.16373956203460693, 7.017120139389369e-33, -0.053280968219041824, 0.07732284069061279, -0.07125693559646606, -0.08184213936328888, -0.0606064572930336, 0.026037396863102913, 0.05477742850780487, 0.03960029408335686, -0.10058383643627167, -0.0009992467239499092, -0.224511057138443, 0.0920608639717102, -0.03927609324455261, -0.016997111961245537, 0.0537043958902359, -0.08372130990028381, -0.01031590811908245, -0.005661068484187126, 0.004187555983662605, -0.03949087858200073, 0.07925080507993698, -0.06717389076948166, -0.02148587256669998, -0.03452114760875702, 0.022089501842856407, -0.07969796657562256, -0.032549403607845306, 0.023871973156929016, -0.16484399139881134, 0.021300576627254486, 0.0031031453981995583, 0.0873609334230423, 0.016733460128307343, -0.08689096570014954, -0.004284248221665621, -0.0709715336561203, -0.02979641780257225, -0.015197081491351128, 0.10214335471391678, -0.010781791992485523, -0.12018290162086487, 0.13062423467636108, -0.11650648713111877, -0.08950373530387878, -0.0697266161441803, 0.009629126638174057, -0.05028785765171051, 0.014383986592292786, 0.05436205863952637, -0.021791942417621613, -0.005753441713750362, -0.04046742618083954, 0.05894354730844498, -0.07925890386104584, -0.10350252687931061, 0.007464373949915171, -0.10383984446525574, -0.10130680352449417, -0.022040095180273056, 0.12141181528568268, 0.0861390084028244, 0.08204516023397446, 0.05014483258128166, 0.0005382273811846972, -0.20352046191692352, 0.24544605612754822, 0.01774778589606285, 0.03179554641246796, 0.06844279915094376, 0.12029868364334106, -0.0012168060056865215, -0.02516176737844944, 0.05016735568642616, -0.07277338951826096, 0.06460529565811157, 0.05591520667076111, -0.003548402339220047, -0.02188725769519806, 0.049396783113479614, 0.020110508427023888, 0.022452479228377342, -0.015452984720468521, -0.02525848150253296, -0.07214124500751495, -0.0008389316499233246, 0.022553663700819016, 0.05237770825624466, 0.05443535000085831, 0.023994244635105133, 0.007104505784809589, 0.030164960771799088, -0.04955487698316574, -0.048441655933856964, 0.004252854734659195, 0.031892213970422745, -7.743970173489037e-33, -0.07977260649204254, 0.09049712121486664, -0.0778539702296257, -0.06368182599544525, -0.07718414068222046, 0.0599755123257637, 0.07221969962120056, 0.04092977195978165, -0.12009723484516144, -0.005294721573591232, 0.0285699050873518, 0.07058539986610413, -0.03787347301840782, -0.00868784636259079, -0.027173014357686043, -0.026666097342967987, -0.01734672673046589, -0.07173583656549454, 0.08142542839050293, -0.12387460470199585, 0.06877297163009644, 0.20155848562717438, -0.13980329036712646, 0.11386316269636154, 0.012527229264378548, 0.04945921152830124, -0.08189009875059128, 0.10787850618362427, -0.01555539295077324, -0.030187219381332397, -0.07838218659162521, 0.022619565948843956, -0.08633287996053696, -0.0046372245997190475, -0.023365309461951256, 0.03968504071235657, 0.009947875514626503, -0.14580771327018738, -0.05371895059943199, 0.02617017552256584, 0.11472152918577194, -0.023179270327091217, 0.07064186781644821, 0.05880594998598099, 0.04500120133161545, 0.009836617857217789, -0.08413970470428467, 0.05759470909833908, 0.21168114244937897, 0.008570627309381962, 0.025631774216890335, 0.0338435135781765, -0.036491893231868744, 0.16336092352867126, -0.10380318760871887, 0.13581901788711548, -0.10505963861942291, -0.01372508704662323, -0.13973325490951538, 0.022422337904572487, -0.011426148004829884, 0.1411624252796173, -0.053041066974401474, -0.03245384246110916, 0.016036979854106903, -0.0520598366856575, -0.006940159946680069, -0.08611730486154556, 0.04774441197514534, -0.046537451446056366, 0.04812368005514145, 0.010442446917295456, 0.05402453988790512, -0.12307078391313553, 0.010855011641979218, 0.14725810289382935, 0.024433866143226624, -0.1369817554950714, -0.07895003259181976, 0.043740011751651764, 0.012434190139174461, 0.04133345186710358, 0.07925525307655334, 0.04628746584057808, -0.17517060041427612, 0.13951891660690308, 0.0530490018427372, 0.028975095599889755, -0.055358875542879105, -0.03899092227220535, -0.03656694293022156, -0.21674340963363647, -0.1404896229505539, -0.06616503745317459, -0.07228407263755798, -1.0039006781425996e-07, 0.014667339622974396, -0.040820203721523285, 0.041937556117773056, -0.060984764248132706, -0.008201589807868004, 0.04505310207605362, -0.023089971393346786, -0.0529961958527565, 0.1063140258193016, 0.11578304320573807, 0.11324039101600647, 0.05891887843608856, -0.1383594423532486, 0.057345855981111526, -0.14984995126724243, -0.01026720181107521, -0.14695197343826294, 0.09610503166913986, -0.06616942584514618, -0.18310049176216125, -0.0038998436648398638, 0.07995544373989105, 0.004787025507539511, 0.02403523400425911, 0.07224965840578079, -0.03561847656965256, -0.07855132222175598, 0.0381026566028595, 0.004337552934885025, 0.13817550241947174, -0.015006784349679947, 0.014740930870175362, 0.12263129651546478, -0.05588608980178833, 0.045627448707818985, 0.028721269220113754, 0.07347343862056732, 0.05857745185494423, 0.08051814138889313, 0.04966866225004196, 0.06415824592113495, -0.0111664067953825, 0.008514969609677792, -0.004864754155278206, 0.025928057730197906, -0.12557020783424377, -0.09153351187705994, 0.01583762839436531, 0.11208213120698929, -0.1851021945476532, 0.1493465006351471, -0.055196888744831085, -0.048954252153635025, 0.04810669273138046, 0.023423461243510246, -0.03510815650224686, -0.2328086793422699, -0.08220323920249939, -0.13331930339336395, 0.016221635043621063, 0.19310948252677917, -0.1736118495464325, -0.0017795469611883163, 0.09931667149066925], "changes": {"1wk": -0.8767114926690924}}, {"text": "LIVE The latest news and updates on Trump's tariffs AxoGen (AXGN) Moves 18.2% Higher: Will This Strength Last? Zacks Equity Research Mon, Jan 13, 2025, 1:05 PM 2 min read In This Article: AXGN TFX AxoGen AXGN shares ended the last trading session 18.2% higher at $18.05. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 6% gain over the past four weeks. AxoGen scored a strong price increase driven by the optimism surrounding the company\u2019s announcement of preliminary unaudited results for the fourth quarter and full year 2024. The company announced that total revenue for the fourth quarter is expected to be approximately $47.5 million, an increase of 15.1% year over year. Full-year 2024 revenue is expected to be approximately $187.3 million, an increase of 17.8% year over year. Per management, the result reflects AxoGen's continued improvements in the execution of commercial strategies, and the continued adoption of Resensation. This regenerative medicine company is expected to post quarterly earnings of $0.03 per share in its upcoming report, which represents a year-over-year change of +150%. Revenues are expected to be $47.5 million, up 10.7% from the year-ago quarter. Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements. For AxoGen, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on AXGN going forward to see if this recent jump can turn into more strength down the road. The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> AxoGen is part of the Zacks Medical - Instruments industry. Teleflex TFX, another stock in the same industry, closed the last trading session 1.9% lower at $174.61. TFX has returned -2.9% in the past month. For Teleflex , the consensus EPS estimate for the upcoming report has changed -0.1% over the past month to $3.86. This represents a change of +14.2% from what the company reported a year ago. Teleflex currently has a Zacks Rank of #4 (Sell). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AxoGen, Inc. (AXGN) : Free Stock Analysis Report Teleflex Incorporated (TFX) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AXGN", "date": "2025-01-13T13:05:00", "sentiment": {"score": 0.819807942956686, "confidence": 0.8579670190811157, "probabilities": {"positive": 0.8579670190811157, "negative": 0.0381590761244297, "neutral": 0.10387387871742249}}, "embedding": [-0.13082383573055267, -0.10197551548480988, 0.042070262134075165, -0.033621810376644135, 0.026436956599354744, -0.05730224400758743, -0.044763557612895966, 0.13199591636657715, 0.06981420516967773, 0.1522100269794464, -0.03825707733631134, 0.12003482133150101, -0.10592345148324966, -0.03494413197040558, -0.14564993977546692, 0.024884536862373352, 0.028493696823716164, -0.09914970397949219, -0.07759232074022293, 0.113979771733284, 0.0187857486307621, -0.02187737450003624, 0.07687985152006149, -0.09059642255306244, 0.09685907512903214, 0.0580904521048069, -0.09949193149805069, 0.01696927472949028, -0.08738649636507034, -0.036609768867492676, -0.06715060025453568, 0.13669641315937042, 0.03932453691959381, -0.08004610240459442, -0.1126200407743454, -0.06166384369134903, 0.00727415643632412, 0.07786593586206436, 0.12865914404392242, 0.02424490451812744, 0.08243007957935333, 0.009882664307951927, -0.12714636325836182, 0.022555824369192123, -0.05992177873849869, -0.12148056924343109, 0.1014077216386795, -0.008635081350803375, 0.03896436467766762, 0.1303456723690033, -0.12288500368595123, -0.04693353921175003, -0.0023795273154973984, 0.06386125832796097, -0.08089946210384369, 0.10271960496902466, -0.03581903129816055, -0.0174110047519207, 0.04371180757880211, 0.06678299605846405, -0.0053265332244336605, 0.08349466323852539, 0.07248052209615707, 0.040115900337696075, 0.17253917455673218, 0.017159435898065567, -0.032728105783462524, -0.012082863599061966, -0.11411892622709274, 0.014374584890902042, 0.040527112782001495, 0.03176853433251381, -0.006670008879154921, -0.0980689600110054, -0.12673330307006836, 0.020862149074673653, 0.1636214405298233, -0.021887540817260742, 0.12735015153884888, -0.09997469186782837, -0.02302495390176773, 0.009718277491629124, -0.00504792295396328, -0.10324910283088684, -1.3480894267559052e-07, -0.06888897716999054, 0.10891257226467133, 0.06054051220417023, 0.06211233511567116, 0.030072756111621857, 0.08261513710021973, 0.012994509190320969, -0.036740656942129135, 0.025667544454336166, 0.038295678794384, 0.04916713386774063, -0.045374076813459396, 0.015435900539159775, 0.051983073353767395, 0.07416356354951859, 0.11198118329048157, 0.08081504702568054, -0.022699378430843353, -0.07817944884300232, -0.09564973413944244, -0.07229573279619217, 0.04570995271205902, -0.0668458491563797, -0.0062725539319217205, 0.1572960913181305, -0.0992712676525116, 0.0897047370672226, -0.11553540825843811, -0.03720498085021973, -0.10629792511463165, 0.046533867716789246, -0.07403872162103653, -0.08046029508113861, 0.06475375592708588, -0.00010866555385291576, 0.13451024889945984, 0.0449061393737793, -0.014682862907648087, 0.062388963997364044, 0.05925167351961136, 0.032668616622686386, -0.044752929359674454, 1.0220801422860892e-32, -0.03261710703372955, 0.08675335347652435, -0.08332735300064087, -0.05649186298251152, -0.008795549161732197, 0.047116465866565704, 0.10191714763641357, 0.048731449991464615, -0.12597770988941193, 0.02023616060614586, -0.2522231340408325, 0.09452597051858902, -0.03526213765144348, -0.00889597088098526, 0.015990000218153, -0.13562580943107605, -0.00841111782938242, 0.0019415314309298992, 0.08454747498035431, -0.019145797938108444, 0.07169504463672638, -0.021082032471895218, -0.05324823781847954, 0.03197691962122917, 0.03708406910300255, -0.0177325326949358, -0.0037316149100661278, 0.04932346194982529, -0.10753868520259857, 0.009779075160622597, -0.032478637993335724, 0.04421595484018326, 0.009676646441221237, -0.10691016167402267, -0.02901342511177063, -0.030961353331804276, -0.011814633384346962, -0.017767153680324554, 0.07809337228536606, -0.025107944384217262, -0.031112411990761757, 0.18116852641105652, -0.008806183002889156, -0.12574824690818787, -0.038609474897384644, -0.06182236224412918, -0.07826727628707886, -0.02045959234237671, 0.02001916989684105, -0.022761736065149307, -0.07674942910671234, 0.00863406527787447, 0.03029465861618519, -0.10025763511657715, -0.06870247423648834, 0.024912014603614807, -0.1771276891231537, -0.059962768107652664, 0.02856259047985077, 0.14528465270996094, 0.07126909494400024, 0.11234600096940994, 0.06106444448232651, 0.05296489968895912, -0.19210900366306305, 0.23169684410095215, 0.058323249220848083, -0.005707352422177792, -0.018805213272571564, 0.10618284344673157, 0.005936956033110619, -0.0520467683672905, 0.04730372875928879, -0.10218548029661179, 0.07886766642332077, 0.02269057184457779, -0.03400854393839836, -0.019757289439439774, 0.05363882705569267, -0.03383798152208328, 0.05965898931026459, -0.03662363439798355, 0.06545794010162354, 0.021213991567492485, 0.0055597275495529175, 0.00780648086220026, -0.03805818408727646, 0.07147728651762009, 0.012266897596418858, 0.04454551264643669, 0.05265304446220398, -0.06815303862094879, -0.12808381021022797, 0.08309555798768997, 0.04603700339794159, -1.0601156864640429e-32, -0.08312727510929108, 0.0745549127459526, -0.07698100805282593, -0.08406870067119598, -0.10799272358417511, 0.1007445752620697, 0.0801154375076294, 0.10847139358520508, -0.0982440710067749, -0.0519455187022686, 0.08437332510948181, 0.07438299804925919, -0.01178993284702301, -0.01987835019826889, -0.09540221840143204, -0.08220288902521133, 0.05882745981216431, -0.04574206471443176, 0.04950443655252457, -0.1495651751756668, 0.061021581292152405, 0.19099608063697815, -0.1280263364315033, 0.10923179239034653, 0.009198600426316261, 0.0601203516125679, -0.016940515488386154, 0.1694275438785553, -0.04081740602850914, -0.06849745661020279, -0.07061905413866043, -0.026649413630366325, -0.1342141032218933, 0.14519073069095612, 0.01765289343893528, 0.05745173990726471, 0.0772758275270462, -0.10522370040416718, -0.029461033642292023, 0.009865688160061836, 0.19554851949214935, -0.01902073435485363, 0.10645255446434021, 0.04796791449189186, 0.03220764175057411, -0.023488430306315422, -0.12514886260032654, -0.03905237466096878, 0.23187077045440674, 0.00804098229855299, -0.03472685068845749, 0.02399902231991291, -0.0157301127910614, 0.06014539301395416, -0.05604839324951172, 0.11119161546230316, -0.021811161190271378, 0.004610423929989338, -0.1539304405450821, -0.044881921261548996, -0.007562900893390179, 0.1478888988494873, -0.024693069979548454, -0.053556833416223526, 0.09463350474834442, -0.03838927298784256, -0.039995744824409485, -0.07441576570272446, 0.12217200547456741, -0.05267215147614479, 0.10362046957015991, 0.00890082586556673, -0.02486402727663517, -0.11650882661342621, 0.02490920200943947, 0.10933180898427963, 0.02599518932402134, -0.20503853261470795, -0.09939059615135193, 0.03654543682932854, 0.06546319276094437, 0.04526323080062866, 0.0987938642501831, 0.030128557235002518, -0.17796891927719116, 0.12390077114105225, 0.03909626975655556, 0.05372938513755798, -0.07694974541664124, -0.024729864671826363, -0.03476188704371452, -0.25269168615341187, -0.22028377652168274, -0.0424993559718132, -0.02629484049975872, -1.0014335316554934e-07, 0.006987481378018856, 0.017405536025762558, 0.08787999302148819, -0.023441310971975327, 0.04315273463726044, 0.015462996438145638, -0.002636035904288292, -0.04303435981273651, 0.08042754232883453, 0.06933002918958664, 0.09721783548593521, 0.05695049464702606, -0.08270452916622162, 0.043962299823760986, -0.1147114634513855, 0.03615647554397583, -0.15995217859745026, -0.0015991861000657082, -0.03822820261120796, -0.21299761533737183, -0.049125786870718, 0.0788176953792572, 0.0017134795198217034, 0.0015924950130283833, 0.06980777531862259, -0.045108675956726074, -0.08746998012065887, 0.08456329256296158, 0.002672064583748579, 0.05740160122513771, -0.06130393221974373, -0.014642355963587761, 0.08969731628894806, -0.037450164556503296, 0.0027095098048448563, -0.07788585871458054, 0.037617459893226624, 0.03689348325133324, 0.042297009378671646, 0.009324252605438232, 0.0099788224324584, 0.0033316845074295998, 0.03476940840482712, -0.0053105428814888, 0.0046802908182144165, -0.08424057811498642, -0.13739342987537384, -0.0295963566750288, 0.15608474612236023, -0.2330838441848755, 0.16453300416469574, 0.024478372186422348, -0.06420573592185974, 0.0044515118934214115, -0.011139661073684692, -0.022780802100896835, -0.2135051190853119, -0.04969506710767746, -0.11637707054615021, -0.0008305646479129791, 0.1336386799812317, -0.20401649177074432, -0.016815971583127975, 0.05017402395606041], "changes": {"1wk": -0.8767114926690924}}, {"text": "LIVE The latest news and updates on Trump's tariffs Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Axogen, Inc. Sat, Jan 11, 2025, 1:00 AM 5 min read In This Article: AXGN Axogen, Inc. Craig Swandal, experienced medical device manufacturing executive, joins leadership team ALACHUA, Fla. and TAMPA, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Craig Swandal as Vice President of Operations. Mr. Swandal will report to Michael Dale, President, and Chief Executive Officer, and will be responsible for manufacturing, supply chain, and infrastructure related strategies and plans. Mr. Swandal will oversee all facets of Operations including tissue processing, distribution, purchasing, planning, manufacturing and process engineering, customer care and continuous improvement. Mr. Swandal is an accomplished executive with more than 25 years of experience leading high growth global manufacturing companies and operations within the highly regulated medical device sector. His experience ranges from small high growth start-ups to Fortune 500 companies within the cardiovascular, visualization and electrosurgical spaces, including leadership experience in global manufacturing strategy planning and execution in companies such as Tendyne (Abbott Labs); Meier Tool and Engineering; ATS Medical; and Gyrus Medical (Olympus). He also served as Director of the Board of APYX Medical from March 2018 until November 2024 and has been a strategic Advisor and member of the Board of Tiumed LLC since April 2018. Mr. Swandal earned his Mini MBA in Medical Technology from St. Thomas University, and a Bachelor of Arts in Organizational Management and Communications from Concordia University. \u201cCraig brings extensive operational leadership experience in regulated medical device manufacturing,\u201d said Michael Dale, Chief Executive Officer, and Director, Axogen. \u201cHis background in scaling operations while maintaining quality standards will be valuable as we continue to advance our manufacturing and operational capabilities.\u201d Craig Swandal, Vice President of Operations, said: \u201cI am excited to join Axogen and look forward to working with the team to support the company's commitment to peripheral nerve repair.\u201d Notice of Issuance of Inducement Grant In connection with the commencement of Mr. Swandal\u2019s appointment as Vice President of Operations on January 9, 2025, and as a material inducement of employment, Mr. Swandal will be awarded an equity grant consisting of: (i) non-qualified Restricted Stock Units (RSUs) representing 58,000 shares of Axogen, Inc. common stock; and (ii) Performance Stock Units (PSUs) representing 58,000 shares of Axogen, Inc. common stock. Story Continues The shares representing the RSUs are subject to vesting over 4 years, with 50% vesting after the second year and 25% of the total shares granted vesting every year thereafter for the next two years. Shares representing the PSUs will vest according to performance metrics tied to the achievement of Company stock price goals between February 22, 2024, and ending February 22, 2027. Mr. Swandal will earn from 0% to 200% of the PSUs upon achievement of these specific Company stock price goals. The inducement awards were approved by the Compensation Committee of the Company\u2019s Board of Directors in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). About Axogen Axogen (AXGN) is the leading Company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven, and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain. Axogen's platform for peripheral nerve repair features a comprehensive portfolio of products that are used across two primary application categories: scheduled, non-trauma procedures and emergent trauma procedures. Scheduled procedures are generally characterized as those where a patient is seeking relief from conditions caused by a nerve defect or surgical procedure. These procedures include providing sensation for women seeking breast reconstruction following a mastectomy, nerve reconstruction following the surgical removal of painful neuromas, oral and maxillofacial procedures, and nerve decompression. Emergent procedures are generally characterized as procedures resulting from injuries that initially present in an ER. These procedures are typically referred to and completed by a specialist either immediately or within a few days following the initial injury. Axogen\u2019s product portfolio includes Avance \u00ae Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; Axoguard Nerve Connector \u00ae , a porcine submucosa ECM coaptation aid for tensionless repair of severed peripheral nerves; Axoguard Nerve Protector \u00ae , a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments; Axoguard HA+ Nerve Protector\u2122, a porcine submucosa ECM base layer coated with a proprietary hyaluronate-alginate gel, a next-generation technology designed to provide short- and long-term protection for peripheral nerve injuries; and Axoguard Nerve Cap \u00ae , a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. The Axogen portfolio of products is available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries. Investor Contact: Axogen, Inc. InvestorRelations@axogeninc.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AXGN", "date": "2025-01-11T01:00:00", "sentiment": {"score": 0.19101263210177422, "confidence": 0.20059597492218018, "probabilities": {"positive": 0.20059597492218018, "negative": 0.00958334282040596, "neutral": 0.789820671081543}}, "embedding": [-0.1752157360315323, -0.21531787514686584, 0.05834616720676422, -0.19260531663894653, -0.08520737290382385, -0.06710737943649292, 0.03854195028543472, 0.12616661190986633, -0.015524600632488728, 0.10810625553131104, -0.030768726021051407, 0.13682079315185547, -0.041533127427101135, 0.137661874294281, -0.1660594791173935, -0.012750386260449886, -0.035399265587329865, -0.11400122195482254, -0.03550300747156143, 0.07135279476642609, 0.06189708039164543, 0.049243178218603134, 0.029710639268159866, -0.1491207480430603, -0.02746669389307499, 0.040653690695762634, -0.06251271069049835, -0.06355905532836914, -0.051998838782310486, -0.06281208246946335, 0.09602198004722595, -0.01249055564403534, -0.004247073084115982, -0.019648443907499313, 0.03207843005657196, 0.07685137540102005, -0.15991081297397614, -0.004525003954768181, -0.1271737962961197, 0.022807341068983078, 0.09350991249084473, -0.05513416603207588, -0.11827513575553894, 0.05162913352251053, 0.13044977188110352, -0.04335416108369827, 0.12143801152706146, -0.09951478987932205, 0.057485323399305344, 0.10558514297008514, -0.12529903650283813, -0.1294538974761963, 0.039209604263305664, 0.02123836800456047, -0.03823157027363777, 0.1669297218322754, -0.017547955736517906, -0.10201893746852875, -0.007225721143186092, -0.02584889531135559, 0.04663024842739105, 0.04430605098605156, 0.04289388656616211, 0.004796694964170456, 0.02147063985466957, 0.03646320477128029, 0.016662130132317543, -0.10037326067686081, -0.1175338476896286, -0.013071209192276001, 0.11598313599824905, -0.0782710462808609, -0.016238607466220856, 0.0789727047085762, 0.016540953889489174, 0.039829179644584656, 0.1433214396238327, 0.03691606968641281, 0.1631288081407547, -0.08386313915252686, 0.09585995972156525, 0.04188944771885872, -0.06212586164474487, -0.00919980276376009, -0.011867837980389595, 0.009137045592069626, 0.05484156683087349, 0.019514821469783783, 0.018427055329084396, -0.08626266568899155, 0.0944809764623642, 0.03316325694322586, 0.0011311164125800133, -0.03688446059823036, -0.019101111218333244, 0.04743148013949394, 0.05838847905397415, 0.05224763974547386, -0.06683822721242905, 0.055197037756443024, -0.04423477500677109, -0.0328756645321846, -0.10710284113883972, -0.051669031381607056, -0.08244743198156357, -0.018143491819500923, 0.026129744946956635, -0.07893022894859314, -0.03465304523706436, 0.06251966208219528, -0.09774383157491684, 0.10467249900102615, -0.11333052814006805, 0.026057466864585876, -0.010735096409916878, 0.01911054737865925, -0.09922905266284943, 0.09101185947656631, 0.10247518122196198, -0.05340474098920822, 0.06950397789478302, 0.02926277369260788, -0.06731516867876053, 0.0023034014739096165, 0.08172313868999481, 0.05594678595662117, -0.08412719517946243, 6.209338788603524e-33, 0.010591288097202778, -0.027860017493367195, -0.04733336716890335, -0.07294577360153198, -0.021206477656960487, 0.11715248972177505, 0.11845280230045319, 0.06515498459339142, -0.004540143068879843, 0.04869893193244934, -0.15523836016654968, 0.048624590039253235, -0.0340992696583271, 0.11141346395015717, -0.046393658965826035, -0.010146399959921837, 0.02088996022939682, -0.03523466736078262, 0.015653369948267937, -0.050174809992313385, 0.022784579545259476, 0.0547763854265213, -0.04851236566901207, 0.15202665328979492, 0.03741932660341263, -0.012084541842341423, -0.038197264075279236, -0.060227442532777786, 0.12111310660839081, 0.060372672975063324, -0.11084077507257462, 0.0757802426815033, -0.01230542454868555, -0.12666143476963043, -0.04220138490200043, 0.07493016868829727, -0.17311593890190125, -0.1997777819633484, -0.01183810830116272, 0.037708818912506104, -0.06363590806722641, 0.10053585469722748, -0.031574055552482605, -0.012841477990150452, -0.05085654556751251, -0.003311536740511656, 0.04246346279978752, 0.023084132000803947, 0.15194180607795715, -0.16690732538700104, -0.11456340551376343, 0.029785973951220512, 0.1583600640296936, -0.12958359718322754, 0.06594115495681763, 0.00835924781858921, -0.15735816955566406, 0.005745393224060535, 0.15855257213115692, 0.10206585377454758, 0.003066025674343109, 0.03185342624783516, -0.018398471176624298, 0.14544929563999176, -0.10574707388877869, 0.028486918658018112, 0.06570303440093994, -0.07006699591875076, 0.06981858611106873, -0.041839346289634705, -0.020252909511327744, -0.08155316114425659, -0.010916637256741524, -0.037346962839365005, -0.1395447701215744, 0.04408256337046623, -0.036214541643857956, 0.12290789186954498, -0.031040973961353302, -0.1558351367712021, -0.139598548412323, 0.14421004056930542, 0.09303788840770721, 0.06436280161142349, 0.14268508553504944, -0.03310875967144966, -0.0009776931256055832, 0.01941278949379921, -0.027415992692112923, 0.032425351440906525, 0.01870429888367653, -0.02543390356004238, -0.0488366074860096, 0.09500634670257568, -0.026702120900154114, -7.104097170458617e-33, -0.08514359593391418, -0.011786073446273804, -0.09093908220529556, -0.0490218847990036, 0.024778205901384354, 0.024806709960103035, 0.041650913655757904, -0.04780266806483269, 0.021859314292669296, -0.1381624937057495, 0.007352958898991346, 0.12107038497924805, -0.056600216776132584, -0.08364543318748474, -0.04886481538414955, 0.005063739605247974, -0.038167066872119904, -0.04705525562167168, -0.01670205034315586, -0.00593301048502326, 0.1484454870223999, 0.2485179901123047, 0.011580094695091248, 0.053683165460824966, 0.004836891777813435, 0.051700904965400696, 0.04964520037174225, 0.07915942370891571, -0.06519816070795059, -0.014244282618165016, -0.06024112179875374, -0.005985906347632408, -0.1792435348033905, -0.011616264469921589, -0.04052920639514923, 0.08262695372104645, 0.06935645639896393, -0.11916040629148483, -0.025231171399354935, -0.012743144296109676, 0.2857356071472168, -0.05933010205626488, 0.0450410358607769, 0.06952568888664246, 0.01089827623218298, -0.1276351511478424, -0.08700059354305267, -0.0930081233382225, 0.07838834822177887, 0.001965317642316222, -0.09695488214492798, 0.06851576268672943, 0.02696577087044716, -0.04718413203954697, 0.013301759958267212, 0.003938350826501846, 0.06242302060127258, -0.07315263897180557, 0.014647109434008598, -0.01646597683429718, 0.08118638396263123, 0.04217623919248581, 0.07099776715040207, 0.0015115290880203247, 0.1288275271654129, 0.11067019402980804, 0.17018914222717285, -0.07658004760742188, -0.031781889498233795, -0.08703000843524933, 0.007034692447632551, 0.017525512725114822, -0.05681535229086876, -0.06102406978607178, 0.016814855858683586, 0.07847781479358673, -0.1029006689786911, -0.20342899858951569, -0.09409414976835251, -0.0422944501042366, 0.08614896237850189, -0.052575282752513885, -0.0003366987220942974, 0.16058573126792908, -0.052094023674726486, 0.052177730947732925, 0.14066463708877563, 0.00976149458438158, -0.04902832210063934, -0.023972313851118088, -0.05582866072654724, -0.18983983993530273, -0.1094081774353981, 0.03150368854403496, -0.018895473331212997, -1.0041000564342539e-07, 0.022428816184401512, 0.11236894130706787, 0.02704223431646824, -0.09006556868553162, 0.028219904750585556, -0.0823870450258255, -0.06277308613061905, 0.03785768896341324, 0.06668466329574585, 0.0953509658575058, 0.06710997968912125, 0.05100734159350395, 0.059145085513591766, 0.04554290324449539, 0.061840564012527466, 0.11812855303287506, -0.09661692380905151, 0.12740273773670197, -0.15320324897766113, -0.1677275151014328, -0.0575624518096447, 0.10837747156620026, 0.0019961269572377205, 0.054888978600502014, 0.05674823373556137, -0.07547282427549362, -0.04702773690223694, 0.12266616523265839, -0.005611344240605831, 0.038744185119867325, -0.06665455549955368, 0.005678433924913406, 0.17396976053714752, 0.03623845800757408, -0.0022066948004066944, -0.11663283407688141, 0.09778350591659546, 0.03824218735098839, 0.08090400695800781, -0.01850772649049759, -0.1466371864080429, 0.05353890359401703, 0.0990166887640953, 0.0005137026309967041, -0.015434630215168, -0.11806993931531906, -0.06929463893175125, -0.049858711659908295, 0.0512220561504364, -0.021806586533784866, 0.02586304396390915, -0.05848130211234093, 0.013644842430949211, 0.0202482882887125, 0.01649342104792595, -0.052421316504478455, -0.06472332775592804, -0.08508771657943726, -0.04098767787218094, 0.045881859958171844, 0.04333456978201866, -0.19383102655410767, 0.0895858108997345, 0.06584206968545914], "changes": {"1wk": 0.22161172974020535}}, {"text": "LIVE The latest news and updates on Trump's tariffs Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2024 Axogen, Inc. Fri, Jan 10, 2025, 4:00 PM 6 min read In This Article: AXGN Axogen, Inc. ALACHUA, Fla. and TAMPA, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary unaudited fourth quarter and full-year 2024 key financials. Preliminary Fourth Quarter and Year-End Key Business Highlights Fourth quarter revenue is expected to be approximately $49.4 million, which represents a 15.1% increase over the fourth quarter of 2023 driven by solid performance across the product portfolio. Full-year 2024 revenue is expected to be approximately $187.3 million, which represents a 17.8% increase over the full-year of 2023. Our positive performance reflects continued improvements in the execution of our commercial strategies, including a focus on high-potential accounts in Extremities and OMF-Head & Neck applications, adoption of Axogen\u2019s complete peripheral nerve surgical algorithm across all procedures, and continued adoption of Resensation \u00ae as an expectation for post mastectomy breast reconstruction procedures. We expect full year gross margin to be above 75.5%. Total balance of cash, cash equivalents and investments on December 31, 2024, is expected to be approximately $39.5 million, representing an increase of approximately $2.5 million over that balance at the end of 2023. \"We are pleased with our fourth-quarter and full-year 2024 performance, which reflects continued improvements in effectiveness and efficiency across the business,\u201d said Michael Dale, President and Chief Executive Officer of Axogen. \u201cLooking to the future, on March 4 th , 2025, we look forward to hosting an Investor Day at which we will share our strategic priorities for the future and the work we believe will best advance our mission to make peripheral nerve care, standard-of-care for all patients.\u201d The results disclosed in this press release are preliminary and unaudited. The Company expects to report full, audited results for the fourth quarter and year ended December 31, 2024, on or before Investor Day. About Axogen Axogen (AXGN) is the leading Company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven, and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain. Story Continues Axogen's platform for peripheral nerve repair features a comprehensive portfolio of products that are used across two primary application categories: scheduled, non-trauma procedures and emergent trauma procedures. Scheduled procedures are generally characterized as those where a patient is seeking relief from conditions caused by a nerve defect or surgical procedure. These procedures include providing sensation for women seeking breast reconstruction following a mastectomy, nerve reconstruction following the surgical removal of painful neuromas, oral and maxillofacial procedures, and nerve decompression. Emergent procedures are generally characterized as procedures resulting from injuries that initially present in an ER. These procedures are typically referred to and completed by a specialist either immediately or within a few days following the initial injury. Axogen\u2019s product portfolio includes Avance\u00ae\u00a0Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; Axoguard Nerve Connector\u00ae, a porcine submucosa ECM coaptation aid for tensionless repair of severed peripheral nerves; Axoguard Nerve Protector\u00ae, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments; Axoguard HA+ Nerve Protector\u2122, a porcine submucosa ECM base layer coated with a proprietary hyaluronate-alginate gel, a next-generation technology designed to provide short- and long-term protection for peripheral nerve injuries; and Axoguard Nerve Cap\u00ae, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. The Axogen portfolio of products is available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries. Cautionary Statements Concerning Forward-Looking Statements This press release contains \u201cforward-looking\u201d statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events, or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as \u201cexpects,\u201d \u201canticipates,\u201d \u201cintends,\u201d \u201cplan(s),\u201d \u201cbelieves,\u201d \u201cseeks,\u201d \u201cestimates,\u201d \u201cprojects,\u201d \u201cforecasts,\u201d \u201ccontinue,\u201d \u201cmay,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cgoals,\u201d and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements include, but are not limited to, statements regarding our preliminary, unaudited fourth quarter and full year 2024 performance, statements related to our mission of making peripheral nerve care, standard of care for all patients, and statements related to our expectations regarding adoption of breast Resensation\u00ae, as well as statements under the subheading \" Preliminary Fourth Quarter and Year-End Key Business Highlights.\" Actual results or events could differ materially from those described in any forward-looking statements as a result of various factors, including, without limitation, potential disruptions caused by leadership transitions, global supply chain issues, record inflation, hospital staffing issues, product development, product potential, expected clinical enrollment timing and outcomes, regulatory process and approvals, APC transition timing and expense, financial performance, sales growth, surgeon and product adoption, market awareness of our products, data validation, our visibility at and sponsorship of conferences and educational events, global business disruption caused by Russia\u2019s invasion of Ukraine and related sanctions, geopolitical conflicts in the Middle East, as well as those risk factors described under Part I, Item 1A., \u201cRisk Factors,\u201d of our Annual Report on Form 10-K for the most recently ended fiscal year and Part II, Item 1A., \u201cRisk Factors,\u201d for our Quarterly Report on Form 10-Q for the most recently ended fiscal quarter. Forward-looking statements are not a guarantee of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made and, except as required by applicable law, we assume no responsibility to publicly update or revise any forward-looking statements. Investor Contact: Axogen, Inc. InvestorRelations@axogeninc.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AXGN", "date": "2025-01-10T16:00:00", "sentiment": {"score": 0.9268115162849426, "confidence": 0.937381386756897, "probabilities": {"positive": 0.937381386756897, "negative": 0.010569870471954346, "neutral": 0.05204875022172928}}, "embedding": [-0.09246888756752014, -0.13105881214141846, 0.07646755129098892, -0.12875661253929138, 0.02014119364321232, -0.0595749169588089, -0.026716025546193123, 0.12982429563999176, 0.011372172273695469, 0.15219718217849731, -0.027110524475574493, 0.07250989973545074, -0.08118700981140137, 0.02931511588394642, -0.1443527340888977, -0.025453928858041763, 0.04418700188398361, -0.05965125560760498, -0.10183548927307129, 0.11952337622642517, 0.12835340201854706, -0.041496045887470245, 0.048963937908411026, -0.10256071388721466, 0.008296485990285873, 0.0029845060780644417, -0.10430020838975906, -0.044789526611566544, -0.07750684767961502, -0.0006236779736354947, 0.03830118104815483, 0.08778728544712067, 0.024611735716462135, -0.1151794046163559, -0.026246782392263412, -0.016632169485092163, -0.07146177440881729, 0.009793615899980068, -0.011189152486622334, 0.09921401739120483, 0.06770355999469757, -0.05907105281949043, -0.09083245694637299, 0.10886803269386292, 0.06829788535833359, -0.08037540316581726, 0.03286609798669815, 0.019534211605787277, 0.031387437134981155, 0.1565309762954712, -0.12072540819644928, -0.10772933065891266, -0.018361637368798256, 0.0389053076505661, -0.05184917896986008, 0.06668036431074142, -0.08969658613204956, -0.10543711483478546, -0.03277327120304108, 0.022296497598290443, -0.014183370396494865, -0.024719681590795517, 0.03750046715140343, 0.02802666835486889, 0.11383979022502899, 0.010255919769406319, -0.019532959908246994, -0.08604807406663895, -0.15831878781318665, 0.023522263392806053, 0.13406777381896973, -0.07544563710689545, 0.04076088219881058, -0.0660201758146286, -0.04483770579099655, 0.013706305995583534, 0.2329140156507492, 0.09152758121490479, 0.13014806807041168, -0.10370150208473206, 0.0489809587597847, 0.03633751720190048, -0.008492845110595226, -0.08080658316612244, -0.04178670048713684, -0.0007100417278707027, 0.05203329771757126, 0.019676368683576584, 0.016916481778025627, 0.0417153462767601, 0.05848028138279915, 0.008285900577902794, -0.016476023942232132, -0.03614146262407303, -0.04394470900297165, 0.0805700421333313, -0.022067178040742874, 0.0008154064416885376, 0.05144546926021576, 0.07150552421808243, 0.0772508829832077, 0.015722695738077164, -0.03312353417277336, -0.17190086841583252, -0.08911053836345673, -0.10665303468704224, -0.000491873943246901, -0.04280192777514458, -0.03837233781814575, 0.10775534063577652, -0.12417066097259521, 0.07978498935699463, -0.06984792649745941, 0.05399884283542633, -0.04453538730740547, 0.11945535242557526, -0.0744214802980423, -0.07729049772024155, 0.20216324925422668, -0.043688416481018066, 0.08595995604991913, 0.08310900628566742, 0.03155561536550522, -0.004823422059416771, -0.01481715776026249, -0.06757085770368576, -0.08013000339269638, 6.095709259839303e-33, -0.07284042239189148, 0.0551542267203331, -0.0428810641169548, -0.09231457859277725, -0.053703565150499344, 0.05113096535205841, 0.06561684608459473, 0.05825764685869217, -0.13918444514274597, 0.02818552777171135, -0.1885826736688614, 0.10817458480596542, -0.014959825202822685, 0.10126462578773499, 0.03686230629682541, -0.0904255211353302, -0.014121072366833687, 0.06677532196044922, 0.06852100789546967, -0.050325147807598114, 0.10843543708324432, -0.02411278896033764, 0.007339991629123688, 0.11793214082717896, 0.03384485840797424, 0.01160120777785778, -0.0645611584186554, -0.007532136514782906, 0.009989775717258453, 0.025380730628967285, -0.04102424904704094, 0.08271807432174683, 0.04772959649562836, -0.156606063246727, -0.1288563460111618, -0.04201711341738701, -0.007072221487760544, -0.12514005601406097, 0.05285688489675522, 0.012949887663125992, -0.059723518788814545, 0.18532514572143555, 0.041998375207185745, -0.09690834581851959, -0.0776720643043518, -0.06212669610977173, 0.037293899804353714, -0.006059490144252777, 0.13226106762886047, -0.06614610552787781, -0.044045593589544296, 0.01033644750714302, 0.07246889173984528, -0.12500891089439392, -0.05923740565776825, 0.012504968792200089, -0.1809413731098175, -0.08083054423332214, 0.04464312270283699, 0.05264834314584732, 0.10207702219486237, -0.015996228903532028, 0.03351332247257233, 0.08613399416208267, -0.15211543440818787, 0.2237797975540161, 0.10881306976079941, -0.049267400056123734, 0.07705201208591461, 0.04828622192144394, -0.0462128221988678, -0.1272079348564148, 0.004041761159896851, -0.04088328033685684, 0.051453471183776855, 0.05053197592496872, 0.038668401539325714, 0.07194766402244568, 0.04999369755387306, -0.02916327491402626, -0.04963795095682144, 0.07241670787334442, -0.00041572097688913345, 0.06423319876194, 0.16230599582195282, 0.057827919721603394, 0.020628802478313446, 0.03608144447207451, 0.012044394388794899, -0.02376079373061657, -0.011504603549838066, -0.039215490221977234, -0.12044017016887665, 0.08683812618255615, 0.032176874577999115, -8.824367766013771e-33, -0.07631771266460419, 0.10027354210615158, -0.024681340903043747, -0.06124156340956688, -0.05076969414949417, 0.012831974774599075, 0.005571838468313217, 0.044844143092632294, -0.012253699824213982, -0.011158343404531479, 0.00730136688798666, 0.0693066269159317, 0.04713437333703041, -0.025091588497161865, -0.10136307030916214, -0.09394419938325882, -0.004508481360971928, -0.08738042414188385, 0.017901014536619186, -0.10216620564460754, 0.14826413989067078, 0.20820340514183044, -0.04353149235248566, 0.03372674435377121, -0.027966482564806938, 0.084374338388443, 0.02861998975276947, 0.11585758626461029, -0.06953035295009613, -0.08278406411409378, -0.09181670099496841, -0.058300167322158813, -0.2264285385608673, 0.01347481831908226, -0.0519084632396698, 0.010666348040103912, 0.0678851306438446, -0.1209489107131958, -0.045990951359272, -0.03500162065029144, 0.1644333004951477, -0.08166211098432541, 0.03243504837155342, 0.10022450983524323, 0.04056782275438309, -0.15959975123405457, -0.07379117608070374, -0.02337302640080452, 0.22906608879566193, -0.0022021401673555374, -0.07216854393482208, 0.08393488079309464, -0.008324598893523216, -0.014611524529755116, -0.09140412509441376, 0.08509786427021027, 0.0802014023065567, -0.10633993148803711, -0.05165426433086395, -0.05118601769208908, 0.00047410372644662857, 0.09288562089204788, -0.0033902721479535103, -0.04462404549121857, 0.1589064598083496, 0.02641265280544758, 0.09291812777519226, -0.1263371855020523, 0.04130202531814575, -0.07581976056098938, 0.040001291781663895, 0.049646973609924316, -0.1500331461429596, -0.11757393181324005, -0.019503546878695488, 0.14473624527454376, 0.03726813197135925, -0.1439698338508606, -0.04966895282268524, 0.03412124142050743, 0.010549142025411129, -0.04557928070425987, 0.09773360192775726, 0.06890776008367538, -0.0475752167403698, 0.005794603377580643, 0.07096352428197861, 0.02273833192884922, -0.13647165894508362, 0.0164372269064188, -0.05776572600007057, -0.17613282799720764, -0.10699422657489777, 0.016749883070588112, -0.040907010436058044, -1.0117653204133603e-07, 0.023360321298241615, 0.16011083126068115, 0.009478104300796986, -0.025396915152668953, -0.019559767097234726, -0.09550720453262329, -0.0750645250082016, -0.013261155225336552, 0.03677240014076233, 0.0639883428812027, 0.06490904092788696, 0.12557652592658997, -0.04379873350262642, 0.04245487600564957, -0.0781719908118248, 0.06696509569883347, -0.12929046154022217, 0.09699231386184692, -0.08174096792936325, -0.13803499937057495, -0.03238385170698166, 0.07352537661790848, -0.007072103209793568, -0.011621387675404549, 0.004312500823289156, -0.013949918560683727, -0.02856927178800106, 0.18014197051525116, -0.054920606315135956, 0.0690712183713913, -0.06026822328567505, -0.006690153852105141, 0.14966043829917908, -0.0704394206404686, -0.04464443773031235, -0.17100471258163452, 0.029848838225007057, 0.035159092396497726, 0.04136253893375397, -0.021004369482398033, -0.02571064978837967, -0.024098141118884087, 0.060117825865745544, 0.03264552727341652, -0.026163706555962563, -0.10059408843517303, -0.13857179880142212, -0.032847821712493896, 0.11808759719133377, -0.08279609680175781, 0.11106617003679276, -0.04416494071483612, -0.06303773820400238, -0.010964520275592804, 0.009939351119101048, 0.0024465005844831467, -0.11294177919626236, -0.06931515038013458, -0.06714773178100586, 0.10476671159267426, 0.1507108509540558, -0.22264038026332855, 0.004279706627130508, 0.01982571743428707], "changes": {"1wk": 2.105269164416418}}, {"text": "LIVE The latest news and updates on Trump's tariffs AxoGen, Inc. (AXGN) Hits Fresh High: Is There Still Room to Run? Zacks Equity Research Tue, Dec 24, 2024, 5:15 PM 4 min read In This Article: AXGN FME.DE Have you been paying attention to shares of AxoGen (AXGN) ? Shares have been on the move with the stock up 27.6% over the past month. The stock hit a new 52-week high of $17.23 in the previous session. AxoGen has gained 151.7% since the start of the year compared to the -4% move for the Zacks Medical sector and the 4.5% return for the Zacks Medical - Instruments industry. What's Driving the Outperformance? The stock has an impressive record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on November 7, 2024, AxoGen reported EPS of $0.07 versus consensus estimate of $0 while it beat the consensus revenue estimate by 3.5%. For the current fiscal year, AxoGen is expected to post earnings of $0.09 per share on $185.43 million in revenues. This represents a 152.94% change in EPS on a 16.62% change in revenues. For the next fiscal year, the company is expected to earn $0.31 per share on $208.47 million in revenues. This represents a year-over-year change of 251.85% and 12.42%, respectively. Valuation Metrics AxoGen may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level. On this front, we can look at the Zacks Style Scores, as these give investors a variety of ways to comb through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style. AxoGen has a Value Score of D. The stock's Growth and Momentum Scores are A and C, respectively, giving the company a VGM Score of B. In terms of its value breakdown, the stock currently trades at 198.4X current fiscal year EPS estimates, which is a premium to the peer industry average of 28.5X. On a trailing cash flow basis, the stock currently trades at 5X versus its peer group's average of 17X. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective. Zacks Rank We also need to look at the Zacks Rank for the stock, as this supersedes any trend on the style score front. Fortunately, AxoGen currently has a Zacks Rank of #2 (Buy) thanks to favorable earnings estimate revisions from covering analysts. Story Continues Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if AxoGen passes the test. Thus, it seems as though AxoGen shares could still be poised for more gains ahead. How Does AXGN Stack Up to the Competition? Shares of AXGN have been soaring, and the company still appears to be a decent choice, but what about the rest of the industry? One industry peer that looks good is Fresenius Medical Care AG & Co. KGaA (FMS) . FMS has a Zacks Rank of # 2 (Buy) and a Value Score of A, a Growth Score of C, and a Momentum Score of A. Earnings were strong last quarter. Fresenius Medical Care AG & Co. KGaA beat our consensus estimate by 7.14%, and for the current fiscal year, FMS is expected to post earnings of $1.94 per share on revenue of $20.88 billion. Shares of Fresenius Medical Care AG & Co. KGaA have gained 0.5% over the past month, and currently trade at a forward P/E of 14.66X and a P/CF of 4.9X. The Medical - Instruments industry is in the top 22% of all the industries we have in our universe, so it looks like there are some nice tailwinds for AXGN and FMS, even beyond their own solid fundamental situation. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AxoGen, Inc. (AXGN) : Free Stock Analysis Report Fresenius Medical Care AG & Co. KGaA (FMS) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AXGN", "date": "2024-12-24T17:15:02", "sentiment": {"score": 0.20834920182824135, "confidence": 0.24449558556079865, "probabilities": {"positive": 0.24449558556079865, "negative": 0.0361463837325573, "neutral": 0.7193580269813538}}, "embedding": [-0.12832947075366974, -0.06597144901752472, 0.05161263793706894, -0.030986782163381577, 0.015114875510334969, 0.006390318274497986, -0.0630965530872345, 0.10515336692333221, 0.09591817855834961, 0.10809026658535004, -0.08596210181713104, 0.06233300641179085, -0.07316865026950836, -0.052392251789569855, -0.14683517813682556, 0.02820109948515892, 0.0609896220266819, -0.05190048739314079, -0.07447875291109085, 0.15172328054904938, 0.027319032698869705, -0.03874325007200241, 0.05426289886236191, -0.12960059940814972, 0.13653036952018738, 0.0605771467089653, -0.06836871802806854, 0.05397804453969002, -0.10373681038618088, -0.07744227349758148, 0.0005437713116407394, 0.11145668476819992, 0.0784289538860321, -0.015426636673510075, -0.13616806268692017, -0.04027426987886429, 0.053838130086660385, 0.08202517032623291, 0.17132946848869324, 0.0478246733546257, 0.09218166768550873, 0.04535990208387375, -0.032391712069511414, -0.018570007756352425, -0.10354374349117279, -0.08894474804401398, 0.031174607574939728, 0.011111261323094368, -0.019793802872300148, 0.06127355247735977, -0.10248617827892303, -0.055572837591171265, -0.05253620818257332, 0.08155340701341629, -0.028421778231859207, 0.09768633544445038, -0.023616310209035873, -0.05783773586153984, 0.012137791141867638, 0.02314862795174122, -0.016572333872318268, 0.08104769140481949, 0.055631011724472046, 0.015253433026373386, 0.1975955218076706, -0.014062098227441311, -0.028202379122376442, 0.019562723115086555, -0.1208081841468811, 0.021331869065761566, 0.08462756127119064, 0.015532073564827442, -0.038364704698324203, -0.05571763962507248, -0.09074443578720093, 0.019337283447384834, 0.15504230558872223, -0.019121048972010612, 0.12947621941566467, -0.15457502007484436, 0.022732261568307877, 0.0345831923186779, -0.016196787357330322, -0.07850202918052673, 0.039594363421201706, -0.03399050980806351, 0.05641481652855873, -0.02484680525958538, 0.10140916705131531, 0.0233342032879591, 0.009284185245633125, -0.04947813227772713, -0.05585213378071785, -0.033099301159381866, 0.07643038779497147, 0.09864059090614319, -0.01754891872406006, -0.026839910075068474, 0.04500655084848404, 0.13072781264781952, 0.13686518371105194, 0.09688658267259598, -0.0753430724143982, -0.11107280850410461, -0.007560480386018753, -0.08286550641059875, 0.09039433300495148, -0.04102908447384834, -0.05488405376672745, 0.0792076513171196, -0.03005112335085869, 0.07718207687139511, -0.11311118304729462, -0.01821655035018921, -0.11750385910272598, -0.019540591165423393, -0.02117730677127838, -0.0013609202578663826, 0.041757505387067795, 0.04717494547367096, 0.08576378971338272, 0.05097617581486702, -0.016358593478798866, 0.015457574278116226, 0.03831673413515091, -0.014058210887014866, -0.16667023301124573, 6.556615084666953e-33, -0.07109802216291428, 0.07983411848545074, -0.0864127054810524, -0.09908967465162277, -0.04900174215435982, 0.02645096369087696, 0.03370030224323273, 0.01516728661954403, -0.10042867809534073, -0.0035484847612679005, -0.22142338752746582, 0.1111350953578949, -0.04046419635415077, 0.013278728350996971, 0.05172416940331459, -0.08439397811889648, -0.01008986122906208, -0.0032881353981792927, -0.0003150608390569687, -0.029387328773736954, 0.10590159893035889, -0.030396807938814163, 0.0024794668424874544, -0.028366565704345703, 0.020565828308463097, -0.053290825337171555, -0.03978922218084335, 0.039793431758880615, -0.1736873984336853, 0.00962882861495018, -0.015972144901752472, 0.09335107356309891, 0.017611684277653694, -0.08917874097824097, -0.016470860689878464, -0.05185879021883011, -0.017152391374111176, -0.03527066111564636, 0.09448285400867462, 0.009092476218938828, -0.11552058905363083, 0.1423325389623642, -0.1024722084403038, -0.0841865986585617, -0.06884589791297913, 0.03621543198823929, -0.05143975466489792, 0.027833277359604836, 0.05345700681209564, -0.0017355028539896011, -0.0005443831905722618, -0.035676728934049606, 0.052603401243686676, -0.07913307845592499, -0.06961689889431, 0.021328231319785118, -0.13167382776737213, -0.10880230367183685, -0.01601267233490944, 0.09810971468687057, 0.10488692671060562, 0.07749682664871216, 0.04814409464597702, -0.00044061290100216866, -0.16342031955718994, 0.23254796862602234, 0.00847140047699213, 0.02145257778465748, 0.07328996807336807, 0.0949569046497345, -0.004887787159532309, -0.035269927233457565, 0.025580573827028275, -0.06977176666259766, 0.04953600466251373, 0.03184615820646286, -0.014897465705871582, -0.02105233445763588, 0.05279213935136795, -0.0038348925299942493, 0.012456772848963737, 0.00326973432675004, -0.027178529649972916, -0.0783153623342514, 0.030145246535539627, 0.029485061764717102, 0.05109751224517822, 0.06190919503569603, 0.03592053800821304, -0.009692911989986897, 0.026884455233812332, -0.0858643651008606, -0.05889328196644783, 0.008904030546545982, 0.027084827423095703, -7.70063851298185e-33, -0.11428213864564896, 0.10751465708017349, -0.0904366597533226, -0.07661566883325577, -0.0728168785572052, 0.05600905418395996, 0.0524609349668026, 0.043728843331336975, -0.09031984955072403, -0.0015097148716449738, 0.04989347979426384, 0.05981701612472534, -0.048596013337373734, 0.00763779366388917, -0.04334700107574463, -0.0433276891708374, -0.013173071667551994, -0.07250979542732239, 0.07263005524873734, -0.11830814182758331, 0.0853346586227417, 0.21648144721984863, -0.13781389594078064, 0.11197257041931152, -0.005845832638442516, 0.029778171330690384, -0.06314709782600403, 0.09464442729949951, -0.022003106772899628, -0.03590504825115204, -0.06881393492221832, 0.0062506129033863544, -0.08989978581666946, 0.033919043838977814, -0.02374395728111267, 0.0578102245926857, -0.0023885914124548435, -0.1567889302968979, -0.04182841628789902, 0.01305053848773241, 0.10949614644050598, -0.034881591796875, 0.051590461283922195, 0.047681163996458054, 0.040615007281303406, 0.03177545964717865, -0.0903090238571167, 0.06225535646080971, 0.19670569896697998, -0.02977251261472702, 0.02067844197154045, 0.037754595279693604, -0.06183488667011261, 0.149858295917511, -0.1251453459262848, 0.10841556638479233, -0.08419376611709595, 0.008974977768957615, -0.13766725361347198, 0.010836772620677948, 0.011637134477496147, 0.1434250921010971, -0.05759090185165405, -0.054227299988269806, 0.015998397022485733, -0.04505721479654312, -0.011269684880971909, -0.09949937462806702, 0.06284797191619873, -0.031400393694639206, 0.025658806785941124, 0.0020375014282763004, 0.03161238133907318, -0.11355967819690704, 0.008490021340548992, 0.12185835838317871, 0.03834915906190872, -0.12133293598890305, -0.08780862390995026, 0.05075865983963013, -0.002170766703784466, 0.04907500743865967, 0.07326000928878784, 0.03422660753130913, -0.15467366576194763, 0.13766443729400635, 0.040132518857717514, 0.04171073064208031, -0.06307144463062286, -0.016309896484017372, -0.0352335199713707, -0.20076462626457214, -0.13072669506072998, -0.051396824419498444, -0.08597005903720856, -1.0039774167580617e-07, 0.017717383801937103, -0.04179086536169052, 0.02014034613966942, -0.03424715995788574, -0.026897508651018143, 0.05767589807510376, -0.022345716133713722, -0.05825376138091087, 0.0898696631193161, 0.10137155652046204, 0.11826809495687485, 0.07144312560558319, -0.12475105375051498, 0.04700625315308571, -0.13171376287937164, 0.03846056014299393, -0.13469865918159485, 0.10719473659992218, -0.0740545243024826, -0.16155904531478882, -0.005841359496116638, 0.09671439230442047, -0.013109369203448296, 0.019058873876929283, 0.06473971158266068, -0.008927271701395512, -0.08751609921455383, 0.0251313429325819, -0.018833275884389877, 0.13158521056175232, -0.016465362161397934, 0.045337241142988205, 0.12955260276794434, -0.06376375257968903, 0.03444685786962509, 0.02202994003891945, 0.07369226217269897, 0.05488331988453865, 0.09158995002508163, 0.055192336440086365, 0.048366814851760864, 0.010425307787954807, 0.009835192933678627, 0.004558056592941284, 0.010506024584174156, -0.10679659247398376, -0.09370438754558563, 0.021614456549286842, 0.10201714187860489, -0.17233175039291382, 0.15689519047737122, -0.050369538366794586, -0.05509146302938461, 0.03182843700051308, 0.04207862913608551, -0.05186108872294426, -0.23140573501586914, -0.0878753811120987, -0.11912263184785843, 0.027341365814208984, 0.1779038906097412, -0.16586679220199585, 0.03535539656877518, 0.0772419422864914], "changes": {"1wk": 1.4145113099555269, "1mo": 16.174656357599947}}, {"text": "LIVE The latest news and updates on Trump's tariffs Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year? Zacks Equity Research Thu, Dec 19, 2024, 5:40 PM 2 min read In This Article: AXGN BSX The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is AxoGen (AXGN) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question. AxoGen is one of 1020 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group. The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. AxoGen is currently sporting a Zacks Rank of #2 (Buy). Over the past three months, the Zacks Consensus Estimate for AXGN's full-year earnings has moved 10.6% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend. According to our latest data, AXGN has moved about 110% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of -4.4% on a year-to-date basis. As we can see, AxoGen is performing better than its sector in the calendar year. Boston Scientific (BSX) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 52.3%. In Boston Scientific's case, the consensus EPS estimate for the current year increased 2.5% over the past three months. The stock currently has a Zacks Rank #2 (Buy). Breaking things down more, AxoGen is a member of the Medical - Instruments industry, which includes 86 individual companies and currently sits at #58 in the Zacks Industry Rank. Stocks in this group have gained about 3.1% so far this year, so AXGN is performing better this group in terms of year-to-date returns. On the other hand, Boston Scientific belongs to the Medical - Products industry. This 87-stock industry is currently ranked #82. The industry has moved +8.8% year to date. AxoGen and Boston Scientific could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AxoGen, Inc. (AXGN) : Free Stock Analysis Report Story Continues Boston Scientific Corporation (BSX) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AXGN", "date": "2024-12-19T17:40:13", "sentiment": {"score": 0.7705043703317642, "confidence": 0.7947712540626526, "probabilities": {"positive": 0.7947712540626526, "negative": 0.024266883730888367, "neutral": 0.18096180260181427}}, "embedding": [-0.0890173465013504, -0.15796053409576416, 0.05256558209657669, 0.041905343532562256, 0.03291311115026474, -0.012754171155393124, -0.10152192413806915, 0.14817431569099426, 0.06366322934627533, 0.09389467537403107, -0.13551193475723267, 0.12544046342372894, -0.0773036777973175, -0.047081489115953445, -0.15528655052185059, -0.01094883307814598, 0.060279302299022675, -0.10140737891197205, -0.05850353091955185, 0.13697606325149536, -0.009066088125109673, -0.08420377969741821, 0.08667107671499252, -0.0736733227968216, 0.11408811807632446, 0.07635355740785599, -0.0708204135298729, 0.020981159061193466, -0.05740152299404144, -0.08526052534580231, -0.008429781533777714, 0.11233212053775787, 0.12803524732589722, -0.034300196915864944, -0.1758016049861908, -0.054911479353904724, 0.004756678827106953, 0.05206017941236496, 0.14322176575660706, 0.09156575798988342, 0.08593035489320755, 0.06407580524682999, -0.02087859809398651, -0.023882847279310226, -0.014332355931401253, -0.12349550426006317, 0.02209492027759552, -0.0327361561357975, 0.05658050626516342, 0.09047713875770569, -0.15444551408290863, -0.12620757520198822, 0.019960995763540268, 0.15359583497047424, -0.09109421819448471, 0.0582595020532608, -0.08697499334812164, -0.13211508095264435, 0.015185692347586155, 0.022315246984362602, 0.08113163709640503, 0.12099465727806091, 0.05718546360731125, 0.006683973595499992, 0.14842474460601807, 0.051108114421367645, -0.06558108329772949, 0.04352914169430733, -0.14931899309158325, 0.048765890300273895, 0.10987144708633423, -0.04279720410704613, -0.01320592314004898, 0.04987218230962753, -0.03288991376757622, 0.0533093698322773, 0.1279483139514923, 0.003701664973050356, 0.18763500452041626, -0.0815512165427208, 0.07512921839952469, 0.0011353124864399433, -0.03758102282881737, -0.03452812507748604, -0.007189772091805935, -0.06464159488677979, 0.048167064785957336, 0.03763224184513092, -0.048294179141521454, 0.03897333890199661, 0.0680941492319107, 0.009540822356939316, -0.010884955525398254, 0.014507010579109192, 0.06139587238430977, 0.05042709782719612, -0.013666599988937378, 0.0405765138566494, -0.022750362753868103, 0.08557850122451782, 0.07981409132480621, 0.11910851299762726, -0.041489362716674805, -0.05816904455423355, -0.10659115016460419, -0.10553425550460815, 0.03704671189188957, -0.08352994918823242, 0.040414053946733475, 0.08475053310394287, -0.04507207125425339, 0.14854696393013, -0.19364714622497559, -0.040027081966400146, -0.15531277656555176, 0.015554109588265419, -0.003877321258187294, 0.00209801085293293, 0.05780954286456108, 0.07194650173187256, 0.06923441588878632, 0.07888676971197128, 0.03713354095816612, -0.03064844198524952, 0.14499878883361816, 0.040606774389743805, -0.1695503443479538, 6.679337429576769e-33, -0.007981390692293644, 0.08125045895576477, -0.054199960082769394, -0.08525721728801727, -0.04096463695168495, -0.004017623141407967, -0.015541989356279373, -0.07266309857368469, -0.08975714445114136, -0.016353923827409744, -0.28339940309524536, 0.12713363766670227, -0.023142006248235703, -0.022544603794813156, 0.06977777183055878, -0.05226543918251991, -0.0036771788727492094, -0.023549385368824005, -0.014253603294491768, -0.02231818623840809, 0.08202570676803589, -0.018483467400074005, -0.07493191957473755, -0.0021723229438066483, -0.012211732566356659, -0.07933485507965088, -0.04490469768643379, 0.055405788123607635, -0.12057618051767349, 0.005631021223962307, -0.00918523594737053, 0.11885370314121246, 0.00035551656037569046, -0.08888638764619827, -0.023158032447099686, -0.07218792289495468, -0.015204258263111115, -0.029894083738327026, 0.14133170247077942, -0.014898029156029224, -0.11514255404472351, 0.16024760901927948, -0.06381596624851227, -0.07078786194324493, 0.09057266265153885, 0.015770835801959038, -0.11441586911678314, -0.04353877156972885, 0.07141469419002533, -0.009336184710264206, -0.053289640694856644, -0.03400132432579994, 0.09039904922246933, -0.0326743982732296, -0.03403562307357788, 0.045789685100317, -0.1464359611272812, -0.08077529072761536, -0.013982731848955154, 0.14622582495212555, 0.13907891511917114, 0.11057484149932861, 0.06309102475643158, -0.011338301934301853, -0.15892621874809265, 0.15273348987102509, 0.07257367670536041, 0.00159170338883996, -0.044461872428655624, 0.15912842750549316, -0.024466123431921005, -0.025467876344919205, 0.06850026547908783, -0.060603126883506775, 0.03860369697213173, 0.0016421675682067871, -0.051832664757966995, 0.008029007352888584, 0.006669129244983196, -0.015728281810879707, -0.013938265852630138, -0.04524264857172966, -0.004837976768612862, -0.002738901413977146, -0.011082062497735023, -0.01959535852074623, 0.010136282071471214, 0.035420626401901245, 0.06110604479908943, 0.009601240046322346, -0.02747417986392975, -0.06200024485588074, -0.06274309754371643, 0.0730845034122467, 0.02160746417939663, -7.466250082215671e-33, -0.06548965722322464, -0.0033343788236379623, -0.030356021597981453, -0.035203590989112854, -0.08846971392631531, 0.06662875413894653, 0.1356182098388672, 0.06314012408256531, -0.05845305323600769, -0.00794496014714241, 0.07488372176885605, 0.1388881504535675, 0.016047079116106033, 0.008738509379327297, 0.02618890255689621, -0.021114284172654152, -0.03667324781417847, -0.10802802443504333, 0.04056715965270996, -0.17789649963378906, 0.07891708612442017, 0.20909538865089417, -0.13499721884727478, 0.13333958387374878, 0.04757765680551529, 0.03955704718828201, -0.09039953351020813, 0.18381154537200928, -0.0009520966559648514, -0.09163816273212433, -0.09547112882137299, 0.0780201405286789, -0.07151059806346893, 0.010341295041143894, -0.0504734069108963, 0.11889859288930893, 0.008311576209962368, -0.15590569376945496, -0.045608360320329666, -0.018386270850896835, 0.16929340362548828, -0.01480928622186184, 0.03173144534230232, 0.02183430828154087, 0.09050838649272919, 0.010034263134002686, -0.07943066209554672, 0.05623573809862137, 0.19437578320503235, 0.010945696383714676, -0.04093853384256363, 0.06108621507883072, -0.06316149234771729, 0.11876747012138367, -0.03715096786618233, 0.045396074652671814, -0.1936800181865692, -0.03272364288568497, -0.21847474575042725, -0.01285227295011282, -0.005523216910660267, 0.09629181027412415, -0.05195531249046326, -0.014135437086224556, -0.0014241039752960205, 0.0029737907461822033, 0.026798903942108154, -0.0838632583618164, 0.03264518082141876, 0.01151654776185751, 0.07675336301326752, 0.029492277652025223, -0.06262766569852829, -0.06044098362326622, 0.018965652212500572, 0.1744464635848999, -0.029812296852469444, -0.17815452814102173, -0.14101852476596832, -0.015051618218421936, 0.0773315578699112, 0.03363509103655815, 0.10207536816596985, 0.038844380527734756, -0.20442549884319305, 0.11647462844848633, 0.0867968201637268, -0.011685675010085106, -0.12736204266548157, -0.07257699966430664, -0.06270039826631546, -0.2812116742134094, -0.20712783932685852, -0.08310948312282562, -0.08975190669298172, -1.0052224297396606e-07, 0.052640244364738464, -0.020692771300673485, 0.0847659632563591, -0.11057968437671661, 0.01230529509484768, -0.043290674686431885, -0.03997547924518585, 0.024778012186288834, 0.12012393772602081, 0.1551668345928192, 0.09524944424629211, 0.05850200727581978, -0.15430065989494324, -0.02968733012676239, -0.040080469101667404, 0.06414124369621277, -0.17652499675750732, 0.0892418920993805, -0.058614932000637054, -0.19612285494804382, -0.03760248050093651, 0.07092142105102539, 0.05905630439519882, 0.0035804964136332273, 0.12762214243412018, -0.05477200821042061, -0.052932024002075195, 0.05392692610621452, 0.010396070778369904, 0.11003260314464569, -0.01656648889183998, -0.03682657331228256, 0.15122996270656586, -0.03741955757141113, 0.017530106008052826, -0.044405747205019, 0.060866788029670715, 0.025369390845298767, 0.0839545726776123, -0.016599848866462708, 0.08064381778240204, -0.003848323365673423, -0.028184514492750168, -0.0005296561866998672, -0.002302519977092743, -0.1233678013086319, -0.05393988639116287, 0.01650579273700714, 0.20041492581367493, -0.23330074548721313, 0.1079731434583664, -0.08846000581979752, -0.06095774471759796, 0.02831180766224861, -0.06964673101902008, 0.026553744450211525, -0.2144516259431839, -0.06471499800682068, -0.10457019507884979, 0.009621302597224712, 0.16707172989845276, -0.16888564825057983, 0.07839037477970123, 0.1434999257326126], "changes": {"1wk": 12.659926683318613, "1mo": 21.818179716420293}}]